



e-TENDER NO:- BPPI/DRUG-040/2016

**TENDER FOR SUPPLY OF DRUGS &
MEDICINES**

TO

**Bureau of Pharma Public Sector Undertakings of
India (BPPI)**

For the year 2016-18



BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon 122016

Telephone: 0124-4040759 / 4556751; Fax: 0124-2340370 Website: janaushadhi.gov.in

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

Telephone: **0124-4556751**; Fax: **0124-2340370** Website: janaushadhi.gov.in

**ONLINE TENDER FOR THE SUPPLY OF DRUGS & MEDICINES TO
BUREAU OF PHARMA PSU OF INDIA FOR THE YEAR 2016-2018**

Tender Reference	BPPI/DRUG- 040/2016 Dt. 09/06/2016
Date of availability of tender documents on website	09/06/2016 (Thursday)
Time and date and place pre-bid meeting	11:00 AM on 17/06/2016 (Friday) Bureau of Pharma PSUs of India, IDPL corporate office, IDPL Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon- 122016 (Haryana)
Last date and time for submission of Online Bid	05/07/2016 upto 11:00 A.M.
Time and date of opening of Technical Bid	11:30 AM on 05/07/2016 (Tuesday)
Place of opening of tender	Bureau of Pharma PSUs of India, IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon- 122016 (Haryana)
Address for Communication	Bureau of Pharma Public Sector Undertakings of India, IDPL corporate office Complex, Old Delhi-Gurgaon Road, Dundaheera, Gurgaon- 122016 (Haryana)

Cost of the Tender Document		Rs. 2,250/- (Inclusive of Tax)
Contact Person for clarification if any		1. Sh. Mahadev Agarwal, Manager (Procurement) Phone:- 0124-4040756 Mob:- 9811780789 Email: mahadevpharm.bppi@gmail.com
		2. Mr. Rupak Kumar, Executive (Procurement) Phone:- 0124-4556764/767 Mob:- 7291087675 Email:- proc3.bppi@gmail.com

The tender document can be downloaded from the CPPP e-Procurement Portal <https://eprocure.gov.in> and from the website of BPPI: janaushadhi.gov.in. However the cost of tender form shall be in the form of **Bankers Cheque or Demand Draft from nationalised bank** favouring “Bureau of Pharma Public Sector Undertakings of India “, payable at Gurgaon/Delhi which is to be delivered in original to BPPI within 5 days the time stipulated against ‘ Bid Submission End Date and time ’. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the tender cost instrument must be uploaded to the e-Procurement portal along with other bid documents as prescribed in tender document.

TABLE OF CONTENTS

Sl.No.	Description	Page No.
1.	Last Date and time for submission of ONLINE Tender	7
2.	Eligibility Criteria	7
3.	General Conditions	8
4.	Technical Bid – Cover “A”	9
5.	Price Bid – Cover “B”	12
6.	Opening of Cover “A” and Cover “B” of Tender	12
7.	Earnest Money Deposit	13
8.	Other Conditions	13
9.	Acceptance of Tender	15
10.	Security Deposit and Agreement	16
11.	Methodology for placing orders	17
12.	Supply Conditions	18
13.	Logograms	20
14.	Packing	21
15.	Quality Testing	22
16.	Payment Provisions	23
17.	Handling & Testing Charges	25
18.	Liquidated Damages and other penalties	25
19.	Deduction and other penalties on account of Quality failure	25
20.	Blacklisting in the event of withdrawal from the tender, and Non-Adherence to the Quality Standards and supply schedule	27
21.	Saving Clause	29
22.	Resolution of Disputes	29
23.	Appeal	30
24.	Contacting the Purchaser by the Bidder	30
25.	Fraudulent and Corrupt Practices	31
26.	Jurisdiction	32
27.	ANNEXURE-I (Declaration for eligibility in participating the tender)	33
28.	ANNEXURE-II (Undertaking for acceptance of terms and conditions of Tender Document)	34

29.	ANNEXURE-III (Details of TENDER COST submitted)	35
30.	ANNEXURE -IV (Details of EMD submitted)	36
31.	ANNEXURE –V (Declaration for acceptance of tender conditions and compliance of WHO-GMP)	37
32.	ANNEXURE -VI (Annual Turnover Statement)	38
33.	ANNEXURE -VII (Declaration for logogram)	39
34.	ANNEXURE -VIII (Details of Manufacturing Unit)	46
35.	ANNEXURE -IX (List of Items quoted)	48
36.	ANNEXURE -X (Check List)	49
37.	ANNEXURE –XI (Notarized Under taking)	51
38.	ANNEXURE -XII (Details of requirements for Drugs & Medicines)	52
39.	ANNEXURE -XIII (Performance Security Bank Guarantee)	80
40.	ANNEXURE -XIV (Agreement format)	81
41.	ANNEXURE -XV (Packing Specifications)	85
42.	ANNEXURE -XVI (Mandate Form for RTGS)	88

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

ONLINE TENDER FOR THE SUPPLY OF DRUGS & MEDICINES TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

FOR THE YEAR 2016-18

Jan Aushadhi Scheme is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called Jan Aushadhi Stores (JAS). In order to enable a focused and institutional approach to implement the Jan Aushadhi Campaign in particular, BPPI was established in December, 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for JAS Scheme.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April, 2010. BPPI follows the provisions of GFR, 2005 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

After varied success in last five years and to give a new thrust to Jan Aushadhi Campaign, a New Business Plan has been worked out. It aims to extend the geographical coverage of the scheme, by opening more than 3000 stores during the 12th Plan Period. It is proposed to channelize efforts to popularize the scheme in a few selected states and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – C.E.O, Bureau of Pharma Public Sector Undertakings of India, IDPL Corporate Office, IDPL Complex, Old-Delhi-Gurgaon Road, Dundahera, Gurgaon - 122016 (Haryana) (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India, (hereinafter referred as **BPPI** unless the context otherwise requires)

Tender Inviting Authority invites **Tender for the supply of Drugs & Medicines to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2016-2018.**

1. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDERS.

(a) Online Bids [in two separate Cover {Technical bid (“Cover A”) and price bid (Cover “B”)}] will be submitted till **11.00 A.M. upto 05/07/2016(Tuesday)** on CPP portal i.e. eprocure.gov.in.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions? However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

2. ELIGIBILITY CRITERIA

(a) Tenderer shall be a manufacturer having valid own drug manufacturing unit duly licensed by licensing authorities with valid WHO-GMP(World Health Organisation- Good Manufacturing Practices) Certificate or direct importer holding valid import license. Distributors/Suppliers/Agents are not eligible to participate in the Tenders. Loan licensees are allowed provided the average annual turnover of bidding company should be at least Rs. 100 Crores for last three years and the average annual turnover of Host Firm (actual manufacturer) should be minimum Rs. 10 crores during the last 3 years.

(b) Average Annual turnover in the last three years i.e. 2012-13, 2013-14 and 2014-15 shall not be less than **Rs. 10 Crores**. For loan licensees, average annual turnover should be at least 100 crores in last 3 years.

(c) Tender should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs and medicines *at the time of submission of online bid*.

(d) The Company/Firm which has been blacklisted/debarred/de-registered/banned by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting/debarred/de-registration *at the time of submission of online bid*.

(e) (i) The Tenderer should upload Scanned copy of a notarized affidavit that they have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **ANNEXURE-I**) while submitting online bid. Original Annexure I should reach BPPI within 5 days of technical bid opening date.

(ii) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI alongwith relevant authentic document by the tenderer firm/ company within one month.

(f) While submitting **online bid**, tenderers are required to upload scanned undertaking on letterhead by authorised signatory confirming that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.(ANNEXURE – II).

3. GENERAL CONDITIONS.

(i) The tender document shall be download from the websites janaushadhi.gov.in; and CPP portal i.e. eprocure.gov.in. However **Tender cost** Rs. 2250/- shall be in the form of **Bankers Cheque or Demand Draft from nationalised bank** favouring “Bureau of Pharma Public Sector Undertakings of India “ , payable at Gurgaon/Delhi which is to be delivered in original to BPPI within 5 days of the time stipulated against ‘ Bid Submission End Date and time ’. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the tender cost instrument must be uploaded (ANNEXURE III) to the e-Procurement portal. Tender cost in any other form like *cheque/cash/postal order* etc. **will not be accepted. The Bid without tender cost shall be summarily rejected.**

(ii) **EMD (Earnest Money Deposit)** : EMD of Rs. 1,00,000/- (Rupees One Lakh only as specified in Clause 7 of the Tender document in the form of **Bankers Cheque or Demand Draft from nationalised** favouring “Bureau of Pharma Public Sector Undertakings of India “ , payable at Gurgaon/Delhi which is to be delivered in original to BPPI within 5 days of the time stipulated against ‘ Bid Submission End Date and time ’. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMD instrument must be uploaded (ANNEXURE IV) to the e-Procurement portal. EMD in any other form like *cheque/cash/postal order* etc. **will not be accepted. The Bid (in case not exempted for EMD as mentioned in tender document) without EMD shall be summarily rejected.**

(iii) Tenders will be opened online. However, authorized representatives of bidder who like to attend online bid opening on the specified date and time should bring letter of authority authorising to attend online bid opening on the printed letter head of the company.

(iv) (a) At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment uploading on website on janaushadhi.gov.in; and CPP portal i.e. eprocure.gov.in will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website janaushadhi.gov.in; and CPP portal i.e. eprocure.gov.in for which BPPI will not issue any separate communication to them.

(v) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(vi) Certain products are reserved for purchase from Central Public Sector Undertakings (CPSU's). Orders for these items will be first placed with CPSU's.

3.1 SPECIAL CONDITIONS.

(i) Bids shall be submitted online only at CPPP website: <https://eprocure.gov.in>. Manual bids shall not be accepted except for the original documents/instruments as mentioned in tender document.

(ii) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e-Procurement Portal <https://eprocure.gov.in>.

(iii) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited and bidder is liable to be banned from doing business with BPPI.

(iv) Bidders are advised to check the *website of BPPI*: janaushadhi.gov.in and CPPP website <https://eprocure.gov.in> at least 3 days prior to closing date of submission of tender for any corrigendum, addendum, or amendment to the tender document.

4. TECHNICAL BID - COVER "A"

4.1. The Tenderer should upload the following documents in while submitting technical bid hereafter called "**Cover A**". (Scanned copies of each page of all documents should be uploaded while submitting Technical bid).

(a) Tender cost as indicated in Clause 3 (i) and Earnest Money Deposit as indicated in Clause 3(ii) and Clause 7 of the tender document shall be in the form of **Bankers Cheque or Demand Draft** favouring "Bureau of Pharma Public Sector Undertakings of India " , payable at Gurgaon/Delhi. Tender cost and EMD in any other form like *cheque/cash/postal order* etc. **will not be accepted.**

(b) Documentary evidence for the constitution of the Company/Firm such as Memorandum and Articles of Association, Partnership deed, Permanent Registration Number etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor. The list of present Directors in the Board of the Company duly certified by a Company Secretary of the Company/Practicing Company Secretary / Chartered Accountant to be uploaded.

(c) The Tenderer should upload Scanned copy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, Scanned copy of same duly receipted by drug authorities must be uploaded along with the validity certificate from state licencing authority (SLA)

(d) Scanned copy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be uploaded. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be uploaded. Original documents should be produced for verification when demanded.

(e) The instruments such as power of attorney, resolution of board etc., authorizing an officer of the Tenderer as the Authorized signatory of the Company/Firm should be uploaded.

(f) Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the BPPI to be uploaded.

(g) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be uploaded with list of items) **for minimum 3 batches of medicine.** In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be uploaded. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but supplies will be accepted only in International Non-proprietary Name (INN) / generic name. **However, for those newly launched drugs and medicines whose first product permission to manufacture and sale has been issued within 2 years by the respective country's / state drug authority, MARKET STANDING CERTIFICATE (MSC) issued by the respective country's /STATE LICENSING AUTHORITY under generic or brand name as a Manufacturer for less than 2 years shall be acceptable to BPPI.**

(h) Scanned copy Non-conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted should be uploaded. The certificate should not be more than 6 months old at the time of submission of technical bid.

(i) Scanned copy of Valid WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate as per schedule 'M' (for manufacturer only) issued by the Licensing

Authority should be uploaded. The Tenderer shall also upload Scanned copy of a notarized declaration in the format given in **ANNEXURE-V** declaring that the Tenderer complies with the requirements of WHO-GMP(World Health Organisation-Good Manufacturing Practices) **as per Schedule-‘M’**. In case of Imported drugs and medicines, labels and product literature of all quoted product(s) must be uploaded with WHO-GMP/certificate which is at par with WHO-GMP issued by exporting countries like U.S. FDA etc/COPP certificate of their Principal Manufacturing company/firm. Original Annexure V should reach BPPI within 5 days of technical bid opening date.

(j) Scanned copy of Annual turnover statement for 3 years i.e. 2012-13, 2013-14 and 2014-15 should be up-loaded in the format given in **ANNEXURE-VI** duly certified by the chartered Accountant.

- (k) a. Scanned copy of Latest Sales Tax Clearance certificate/returns are to be uploaded (In case Sales Tax is exempted, the documentary evidence with nil returns are to be uploaded).
b. Scanned copy Latest Income tax assessment orders/returns filed are to be uploaded.

(l) (i) Scanned copy of undertaking (as in the proforma given in **ANNEXURE-VII**) for embossment of logos on strip of tablets, capsules, on labels of vials, Ampoules, bottles, tubes etc. as the case may be, and for supply of tablets/capsules in strips as per conditions specified under Clause 13 is to be uploaded.

(ii) Scanned copy of undertaking (as in the proforma given in **ANNEXURE-VII (A)**) for affixing the logo on the Secondary/Primary packing for the imported items along with Brand/Trade names is to be uploaded.

(m) The details containing the name and address of the manufacturing premises / importing unit where the items quoted are actually manufactured should be uploaded as per the format in **ANNEXURE-VIII** along with exact address of registered/Corporate office.

(n) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable.

(o) The loan license bidder are required to upload scanned copies of all the documents as per tender requirements for own manufacturing unit plus 10 crores average annual turnover of host company/actual manufacturer.

(p) List of items quoted (The name & Drug code of the Items quoted as shown in the **ANNEXURE-IX** should be uploaded and **the rate of those items should not be indicated in this list**),

(q) A Checklist (**ANNEXURE- X**) shall be uploaded with technical bid. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but

necessary document regarding separate manufacturing units will be uploaded as a separate set with the same tender. However one bidder will be allowed to submit only one offer for one product.

(r) All the documents uploaded should also be signed by the authorized official of the Tenderer.

4.2. The all documents indicated above should be uploaded and shall be opened at the time date of Technical bid opening.

5. PRICE BID - COVER "B"

5.1. Cover "B" contains the Price Bid of the Tenderer.

(i) (a) The Tenderer shall fill in manufacturing capacity, the landed price, total value, rate of CST against form C and Central excise duty applicable (yes/no) in respective column of for the items quoted and also in BOQ.

(ii) **Determination of L1 bidder:** In determining the lowest evaluated price, the rate quoted per unit landed price as indicated in column No. 7 of the **BOQ** shall be taken into consideration.

(iii) The rate quoted in column 7 of **BOQ** should be for a unit and for the given specification. **The rates quoted in paisa are to be in 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the ANNEXURE- XII

EXCISE DUTY-

(vi) The tenderers must indicate the rate of Excise duty applicable and payable by them irrespective of the fact whether the quoted prices are inclusive or exclusive of Excise Duty. If a tenderer states that the Excise duty is NIL/EXEMPTED, he must intimate the basis for the same and also confirm that no Excise Duty will be charged by him under any circumstances.

(vii) In case, no information about excise duty is given, it will be taken as inclusive.

ST/CST/VAT

(viii) The tenderers must indicate the rate of CST **against Form C** applicable.

(ix) In case supply is made from any place in Haryana, VAT shall be applicable.

5.2. If the last date for submission of Tender is declared holiday, the tenders may be submitted on the next working day upto 11.00 A.M.

6. OPENING OF COVER "A" AND COVER "B" OF TENDER

6.1 Only authorized official as indicated in Clause 4.1. (f) are entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation and inspection, will only be informed the time and date of opening of Price Bid - Cover “B” of the tender.

7. EARNEST MONEY DEPOSIT

7.1. The Earnest Money Deposit referred to under Clause 3(ii) & 4.1(a), shall be **Rs. 1 lakh. The Earnest Money Deposit shall be paid in the form of Bankers Cheque or Demand Draft in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi.**

7.2. (i) The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of signing the contract agreement and on the deposit of Security Deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender/signing of agreement with eligible bidder.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non execution of agreement /undertaking within the period prescribed.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract agreement and / or deposit the security Deposit within the stipulated time (**ANNEXURE-XI**). Scanned copy of Annexure should be uploaded. Original Annexure XI should reach BPPI within 5 days of technical bid opening date.

(vi) Tenderer may be exempted from the payment of EMD, provided that valid **registration** certificate from NSIC is uploaded **for the product for which bidder has submitted quotation.**

(vii) PSUs are exempted from the payment of EMD.

8. OTHER CONDITIONS

8.1. (i) The details of the required drugs, medicines, etc., are shown in **ANNEXURE - XII. The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased** by the BPPI, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order

issued time to time within validity of contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the agreement / undertaking.

(iii) The rates quoted shall not be varied with the ordered quantity during the full contract period.

8.2. Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE -XII**. Any variation, if found, will result in rejection of the tender. However the imported/combination drugs are allowed to quote in trade / brand name.

8.3. Rates (inclusive of Customs duty, packing & forwarding charges, transportation, insurance-and any incidental charges, but exclusive **CST against form C/VAT** (Sales Tax) and excise duty) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like “AT CURRENT MARKET RATES” shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5.The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly this clause will be applicable for all orders placed during the contract period.

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction

in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as “SUBJECT TO AVAILABILITY”, “SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED” etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If any such situation arises after placement of contract, the same shall be cancelled at the firm's risk cost.

8.10 “MRP inclusive of all taxes” is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

9. ACCEPTANCE OF TENDER

9.1. Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column 7 of **BOQ**. To have additional source of supply, L1 bidder shall be awarded contract/agreement for 50% of tender quantity indicated in the tender document. Balance 50% of the tender quantity indicated in the tender document shall be awarded to L2 & L3 bidders in the ratio of 30:20 respectively if they agree to supply the drugs at L1 rates. In case, either of L2 or L3 bidder does not agree to match L1 rate, balance 50% quantity shall be awarded to any of these two bidders who agrees to match L1 rate. In case, both L2 and L3 bidders do not agree to match L1 rate, 100% tender quantity shall be awarded to L1 bidder. The purchase order shall be issued to L1 bidders and in case they fail to supply in stipulated time, the purchase order shall be issued to L2 bidder. Similarly, if L2 bidder fails to supply drug in stipulated time, the purchase order shall be issued to L3 bidder. During the agreement period of 2 years, in case L1 bidder completes the supply of drugs for contracted quantity, next supply shall be taken from L2 & L3 bidders accordingly for contracted quantity. The splitting of quantity in ratio of 50:30:20 shall not be applicable in case L1 rates are quoted by more than one bidder and quantity will be shared as per clause no. 11(c). Further, splitting of quantity shall also not be applicable in case only one bid is received. However, quantity shall be splitted in the ratio of 50:50 in case only 2 bids are received. The issue of purchase orders in same manner as mentioned above. Negotiation if required will be done at our premises and the same will be done strictly as per Central Vigilance Commission guidelines.

9.2. BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

9.3. BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

9.4. The acceptance of the tenders will be communicated to the lowest Tenderers in writing.

10. SECURITY DEPOSIT AND AGREEMENT

10.1 Security Deposit:

On being informed about the acceptance of the tender and at the time of signing the Agreement, the Tenderer shall pay the Security Deposit @ 5% of the value of order in the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Pharma Public Sector Undertakings of India from any scheduled Bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond 3 months of the validity of the contract. The format of Bank Guarantee is at **ANNEXURE-XIII**.

10.2. The Tenderer shall execute an agreement on a non- judicial stamp paper of value of Rs.100/- (stamp duty to be paid by the Tenderer) within 15 days from the date of the intimation from BPPI informing that his tender has been accepted. The Specimen form of agreement is available in **ANNEXURE-XIV**.

10.3. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

10.4. All notices or communications relating to and arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.5. If the lowest Tenderer fails to execute the agreement and/or to deposit the required security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions.

10.6. The security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters.

11. METHODOLOGY FOR PLACING ORDERS

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed.

(b) The Successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security and on execution of the agreement.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers shall execute necessary agreement as specified in the Tender Document on depositing the required amount as Performance Security and on execution of the agreement such Tenderer's are eligible for the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders subject to their manufacturing capacity.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If a supplier fails to execute 3 successive supply orders successfully, their security deposit shall be FORFEITED and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI with stipulated delivery period including L.D. Period.

(f) Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, agreement and purchase order.

(g) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon within the stipulated period.

(h) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(i) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

(j) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice.

(k) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(l) Subject to above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made within 30 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(m) Subject to the conditions mentioned in the Purchase Order, Tender Document, Agreement executed by the supplier and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(n) BPPI reserves the right to place up to 50% additional purchase order of the quantities as contracted within validity of contract.

12. SUPPLY CONDITIONS

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon.

12.2. Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

12.3. The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order. In case no response is received from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and BPPI shall purchase the drugs from alternative sources.

12.4. (a) For the first purchase order, the supplier must supply the ordered quantity CWH Gurgaon within 60 days from the date of Purchase Order.

(b) For Subsequent purchase orders, the supplier shall complete the supply within 45 days from the date of purchase order at the destinations mentioned in the purchase order.

(c) If the above day for 12.4 (a) & (b) above happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

(d) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

(e) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18.

(f) The supplier may continue the supply of unexecuted quantity after 60th day in case of 12.4(a) above and after 45th day in case of 12.4(b) above, however Liquidated Damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied on the quantity supplied after the 60th day and 45th day respectively. However, no supplies will be accepted after 120 days from the date of issue of purchase order and the purchase order shall be cancelled at the risk and cost of the supplier.

12.5. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders.

12.6. The supplied Drugs (covered in SCHEDULE “P” of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias. **However, in case of thermolabile drugs not covered in SCHEDULE “P” of Drugs and Cosmetics Act, the minimum shelf life should be 2 years from the date of manufacture.**

12.7. The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will

be returned back to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with the specifications, stipulations and conditions specified in the tender.

12.8. Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015. For sterile products having shelf life of 18 months or more, products within 90 days (3 months) from date of manufacture will be accepted.

For imported products, 75% of shelf life should be available at time of supply.

12.9. The order stands cancelled at the end of 90th day from issue of Ist Purchase order/ from issue of the subsequent purchase order after levying penalty on the value of unexecuted order as specified under Clause 18.3. Further, the Tenderer shall also be liable to pay other penalties as specified under Clauses 18. Security Deposit of such suppliers against the contract/agreement shall also be forfeited. Their tender/offer against future tender of BPPI shall not be considered keeping in view of bad performance in previous contract/agreement.

12.10. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.11. The supplier shall not be liable to pay LD and forfeiture of security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

13. LOGOGRAMS

Logogram means, wherever the context occurs, the design as specified in **ANNEXURE-VI. The name of the drug shall be mentioned in English and Hindi.**

13.1. Tenders for the supply for Drugs etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **ANNEXURE –VI &VI -A.**

13.2. All tablets and capsules have to be supplied in packing as specified in product list (**ANNEXURE XII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed Jan Aushadhi logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

14. PACKING

14.1. The drugs shall be supplied in the package specified in **ANNEXURE - XII** and **ANNEXURE -XV** and the package shall carry the logograms of proportionate size specified in **ANNEXURE –VII, VII -A**. Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing and strip packing should be 70mm x 30 mm and 50mm x 130mm respectively. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5.

14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-XV**. The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350 GSM. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only first-hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drugs & medicines supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

14.10. Designs of packaging with the logograms shall be subject to approval by BPPI within 7 days of receipt of the same from the supplier, as per the specifications. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in **ANNEXURE XII and XV**.

15. QUALITY TESTING

15.1. Samples of supplies from each batch will be chosen at the point of despatch or receipt of supply or distribution/storage points for testing at discretion of BPPI. The samples will be sent to different laboratories including Government Drugs Testing Laboratory for testing as decided by the BPPI Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

15.2. The Drugs and medicines shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found “Not of Standard Quality”, the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

15.3. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

15.4. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

15.5. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country's Pharmacopoeial standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happens more than twice in a tender period such cases will be treated as "Misbranded Drugs".

16. PAYMENT PROVISIONS

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original (**ANNEXURE -XVI**) to make the payment through RTGS/Core Banking/NEFT.

16.3. All bills/Invoices should be raised in triplicate and in the case of excisable Drugs , the bills should be drawn as per Central Excise Rules in the name of Bureau of Pharma Public Sector Undertakings of India. IDPL Complex, Dundahera, Gurgaon 122016 or in the name of any other authority as may be designated.

16.4. (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within 60 days from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6.(a) In case of any increase or decrease in the taxes, such as excise duty, customs duty, sales tax, VAT etc., after the date of submission of tenders and during the tender period, such variation in the taxes will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned Excise authorities and also must claim the same in the invoice separately. However the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly if there is any reduction in the taxes and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender.

Any increase or decrease in taxes and statutory levies will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated Delivery period, increase in Excise duty/taxes due to statutory variation in Excise duty/taxes shall be borne by the supplier. In case of decrease in Excise duty/taxes due to statutory variation in Excise duty/taxes, the same shall be passed on by the supplier to the BPPI.

(b) In case of successful bidder enjoying excise duty exemption on any criteria of turnover, area based etc., such bidder will not be allowed to claim excise duty at a later point of time, during the tenure of contract, when the excise duty is chargeable on goods manufactured.

16.7. Form 'C' shall be provided by BPPI, wherever required. The tenderers should quote the concessional rate of CST applicable in their bids.

17. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

18. LIQUIDATED DAMAGES AND OTHER PENALTIES:

18.1. If the supply reaches the designated places or Central Warehouse after 5 PM of 60th day from the date of issue of the 1st purchase order and after 5 PM of the 45th day from the date of issue of the subsequent purchase order, a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 60th/45th day happens to be a holiday the supply will be accepted on the next working day without any penalty.

18.2. If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

18.3. All the Tenderers are required to supply the product(s) with printed logogram of appropriate size on the strips, blisters, vials, ampoules & bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the receipt of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated.

19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be

entitled to any payment whatsoever for Items of drugs found to be of “NOT OF STANDARD QUALITY” whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

19.3. For the supply of Adulterated/Spurious/Misbranded drugs, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Security deposit will also be forfeited without any intimation.

19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days’ notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Security deposit.

19.6. For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Security deposit.

19.7. Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Security deposit.

19.8. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Security Deposit or

from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

19.9. In all the above conditions, the decision of the BPPI shall be final and binding.

20. BLACK LISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE

20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

(a) If the Tenderer(s) fails to execute the agreement / to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Security deposit.

BLACKLISTING FOR QUALITY FAILURE

20.2.1. Quality Test by the Empanelled Laboratories of BPPI

a. Each and every batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements.

c. If such sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample fails in quality test and report is received certifying that sample is “NOT OF STANDARD QUALITY”, one more sample shall be drawn from the same batch and to be sent to Government Laboratory for quality testing.

(i) If such sample passes the quality test as per the report of Government Laboratory, the drugs representing the sample shall be qualified for issue to various Institutions.

(ii) If such sample fails in the quality test, as per the report of the Government Laboratory, the drugs of the batch are not qualified for issue and the supplier shall take back the drugs supplied in that batch, besides taking other actions as per the Tender conditions by BPPI.

(iii) If such Sample fails in quality test for ASSAY content of less than 50% as per the Government Analyst report, such product of the tenderer will be blacklisted for two years.

(iv) If 3 batches of a particular item supplied by the supplier is reported to be failing in ASSAY content (above 50% but below prescribed limit) and/or other parameters, then the particular item of the firm shall be blacklisted after observing procedure laid down in Para 20.2.4 besides forfeiture of Security Deposit of that particular product(s).

f. In all the cases the reports received from the Government Drug Testing Laboratory will be conclusive and final and binding on the suppliers.

20.2.2 Quality Test by Statutory Authorities:

(a) On complaint from Drug Inspector(s) during their Test of statutory sample, that the particular drug has been reported to be of “NOT OF STANDARD QUALITY”, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals will be retrieved. If the sample is reported to have less than 50% of content, the particular product will be **blacklisted for 2 years from the date of intimation of blacklisting.**

(b) If 4 batches of a particular item supplied by the supplier is reported to be failing in **ASSAY content (above 50% but below prescribed limit) and/or other parameters.** then the particular item of the firm shall be blacklisted for a period of **2 years** from the date of intimation after observing procedure laid down in Para 20.2.4.

(c) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period, the company/firm shall be blacklisted for a period of **5 years from the date of blacklisting** after observing procedure laid down in Para 20.2.4.

20.2.3 BLACKLISTING OF THE SUPPLIER FOR QUALITY FAILURE:

a. In case of any sample declared as Adulterated/spurious/ Misbranded, as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during, the company/firm shall be blacklisted for a period of **5 years** from the date of intimation besides forfeiture of security deposit in full after observing the procedure laid down in Para 20.2.4.

20.2.4 Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is “**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/ MIS-BRANDED**” (As the case

may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the particular item of the product/company or firm as deemed fit besides forfeiture of Security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

20.3 BLACKLISTING FOR NON-SUPPLY:

Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs as stipulated in the terms and conditions of the tender, the BPPI shall take action against the supplier as follows:

(a) If the supplier fails to execute at least 50% of the ordered quantity as mentioned in a single Purchase order and such part supply for **any three Purchase orders of the same drug**, then the product of the supplier will be blacklisted and becomes ineligible to participate in any of the tenders for that particular item(s) by BPPI for a period of **2 years** from the date of intimation for blacklisting besides forfeiture of security deposit of that product(s)

(b) If the supplier supplies more than one item and 50% of such items are blacklisted, the firm is liable to be blacklisted for a period of **2 years from the date of intimation** besides forfeiture of security deposit in full

20.4. Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.

20.5. The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act 1940 or any other law of Land. BPPI will display names of such blacklisted product(s) and company/firm on its website and also circulate the same among other state Government / Central Government and its Drug procurement agencies including respective State Drugs Control Department where the company or firm is located.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. RESOLUTION OF DISPUTES

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract,

ARBITRATION AND JURISDICTION

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

23. APPEAL:

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India within ten days from the date of receipt of order and the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

24. CONTACTING THE BPPI BY THE BIDDER:

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser's* bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

(iv) Notwithstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

25. FRAUDULENT AND CORRUPT PRACTICES:

(1) For bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. *(In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper)* In pursuance of this policy, the purchaser;

(a) defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution*). In this context, *"public official" includes staff and employees of other organizations taking or reviewing procurement decisions.*

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution*).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level*].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution*).

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

(2) For suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Security Deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) “corrupt practice” is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) “fraudulent practice” is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) “collusive practice” is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) “coercive practice” is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) “obstructive practice” is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb) acts intended to materially impede the exercise of the purchaser’s inspection and audit rights provided for.

26. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

ANNEXURE -I

Ref. Clause No. 2(e)(i)

DECLARATION

I
Managing Director/Partner/Proprietor of M/s.
having its manufacturing or import unit/ registered office at.....do
hereby declare that our company/applied items have not been blacklisted/debarred/de-
registered/banned due to quality failure of the drugs supplied either by any State government
or Central Government Organization or its drug procurement agencies for the following
products quoted in the tender. We are eligible to participate in the tender ref. No.
BPPI/DRUG-040/2016 Dtd. 09-06-2016 for the following products.

S. No.	Drug Code	Name of the Drug

Signed.....

Name

Designation

(Company Seal)

To be attested by the Notary

ANNEXURE-II

{Ref : Clause Para No. 2(f)}

(UNDERTAKING ON LETTER HEAD)

I.....
Managing Director /Partner/Proprietor or authorised signatory of M/s.
.....
having its registered office atand its factory premises at
.....
.....do declare that I/we have carefully read all the terms and conditions of tender
in ref. no. **BPPI/DRUG-040/2016 Dtd. 09-06-2016** including Amendment(s) to Tender
document (if any) issued by Bureau of pharma public sector undertakings of INDIA,
GURGAON, 122016 and accept unconditionally all terms and condition of tender document
including Amendment(s) to Tender document (if any).

Signed.....

Name

Designation

(Company Seal)

ANNEXURE -III

Ref. Clause No. 3(i)

DETAILS OF TENDER COST SUBMITTED

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER

ANNEXURE -IV

Ref. Clause No. 7.1 & 3(ii)

DETAILS OF E.M.D SUBMITTED

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER

ANNEXURE -V

Ref. clause No. 4.1 (i)

DECLARATION

I/We M/s. Represented by its Proprietor/Managing Partner
/Managing Director having its registered office atand its
factory premises at

.....do declare that I/we have carefully read all the conditions of tender in ref.
no. **BPPI/DRUG-040/2016 Dtd. 09-06-2016** public sector under taking of INDIA,
GURGAON, 122016 and accept all conditions of the Tender.

I/We declare that we possess the valid drug manufacturing licence and WHO-
GMP(World Health Organisation-Good Manufacturing Practices) Certificate as per schedule
'M' issued by competent authority and complies and continue to comply with the condition
lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest
Money Deposit and /or Security Deposit and blacklist me/us for a period of 5 years if, any
information furnished by us proved to be false at time the of inspection and not complying
the condition as per schedule M of the said Act for a period of five years.

Signature :

Name &Address:

Seal:

To be Notarized.

ANNEXURE -VI

Ref. Clause No. 4.1(j)

ANNUAL TURNOVER STATEMENT

The annual Turnover of M/s.for the past two years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2012-13	
2.	2013-14	
3.	2014-15	
TOTAL		Rs.....Lakhs
Average Turnover per annual		Rs.....Lakhs

Date:

Signature of Auditor/Chartered Account

Seal:

(Name in Capital)

ANNEXURE -VII

Ref. Clause no 4.1 (l) (i)

DECLARATION

I do hereby declare that I will supply the drug as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer

Name

Designation

(Company Seal)

ANNEXURE –VII(A)

Ref. Clause No. 4.1 (l)(ii)

UNDERTAKING

I / we do hereby declared that I will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Enclosure–1 to ANNEXURE -VII AND VII(A) - Refer Clause No .4.1. (I)

DESIGN FOR: Foil / blister of tablet and capsule

1. **Printing on** Foil /Blister should be in minimum two colour i.e. Black & red. **However, colour and design of BPPI logogram should be as given below.**
2. BPPI Logogram should be placed along with the address as given below
3. BPPI helpline number 1800 180 8080 should be printed
4. Font type should in CALIBIRI format for any type of title name of generic medicines

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

5. Janaushadhi should be printed in “Inverse red colour” in English and Hindi as

Janaushadhi(English) Jan Aushadhi(In Hindi)

Enclosure – 2 to ANNEXURE –VII & ANNEXURE –VII(A)

Ref. Clause No. 4.1.(I) & Clause No. 13

1. Design for injection for primary packing

- a) Vial (5ml or more) should be supplied with the following Jan Aushadhi logogram & BPPI as under:
- b) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

b) Ampoules or Vials less than 5 ml for primary packing

- (i) Injection in ampoule or vial (less than 5 ml) should be supplied with BPPI logogram as under (colour should be black)

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Or

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

2. LIQUID:

- a) Liquid preparation should be supplied with pilfer proof ROPP cap.
- b) Bottle cap should not bear the manufacturer's logogram
- c) Bottle label should bear JANAUSHADHI logogram as below:
- d) BPPI helpline number 1800 180 8080 should be printed



Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

3. OINTMENTS / CREAMS

- a) Ointment / Cream /Gel /Glass Jar should bear BPPI logo gram as below:

Manufactured for :



Bureau of Pharma PSUs of India

IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

- b) BPPI helpline number 1800 180 8080 should be printed
- c) Ointment / cream tube should be packed in mono carton (secondary packing) with janaushadhi and BPPI logogram as given below. **Logo in 4 colors will also be accepted.**



Manufactured for :




Bureau of Pharma PSUs of India


IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

Enclosure 3 to ANNEXURE –VII(A)

SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)

Rx Tablets	10 X 10's
Generic Name of Product	
	

Note: An additional to statutory requirement under Drug & Cosmetic Act 1940 and rules 1945

Manufactured for :	
	Bureau of Pharma PSUs of India IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana)

ANNEXURE – VIII

Ref. Clause No.4.1 (m)

DETAILS OF MANUFACTURING /IMPORTING UNIT

Sl.No.	Details	
1.	Name of the Tenderer & Full Address	
2.	PAN Number	
3.	TIN Number	
4.	Phone Nos.	
5.	Fax	
6.	E-Mail ID	
7.	Date of Inception	
8.	Licence No. & Date	
9.	Issued By	
10.	Valid Upto	

Details of Installed Production Capacity for 1 year

(In Terms of Unit Packs)

S.No.	Details	
1.	Tablets	
	Capsules	
2.	a) General	
	b) Beta-Lactum	
3.	Injections	
	a) Ampoules	
	b) Vials	
	c) I.V. Fluids	
	d) Sterile Powder	
4.	Liquids	
	a) Suspension	
	b) Syrups	
	c) Drops	
5.	Ointment	
6.	Powders	
7.	Antiseptics / Disinfectants	
8.	Name & designation of the authorized Signatory	
9.	Specimen signature of the authorized Signatory	

* The details of manufacturing unit shall be for the premises where items quoted are actually manufactured.

ANNEXURE – IX

Ref. clause 4.1 (p)

LIST OF ITEMS QUOTED

Sl.No.	Details																			
1.	Name of the firm and address (As given in Drug licence)																			
2.	Drug Licence No. in form 25 & 28 Or import Licence No.																			
3.	Date of issue & validity																			
4.	WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate obtained on																			
5.	Non-conviction Certificate Obtained on																			
6.	Market standing Certificate Obtained on																			
7.	Details of Endorsement for all products quoted :																			
<table border="1" style="width: 100%; border-collapse: collapse;"><thead><tr><th style="width: 10%;">Sl.No.</th><th style="width: 10%;">Drug Code</th><th style="width: 20%;">Drug Name</th><th style="width: 20%;">Specifications IP/BP/USP</th><th style="width: 20%;">Date of Endorsement obtained from the State Drugs Controller</th><th style="width: 20%;">Whether Endorsement is in Generic or Trade Name</th></tr></thead><tbody><tr><td>1.</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2.</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>			Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name	1.						2.					
Sl.No.	Drug Code	Drug Name	Specifications IP/BP/USP	Date of Endorsement obtained from the State Drugs Controller	Whether Endorsement is in Generic or Trade Name															
1.																				
2.																				
Authorised signatory: Date:																				

ANNEXURE – X

Ref. Clause 4.1 (q)

CHECK-LIST (Whether Uploaded the documents)

COVER – A

S.No.	Check List	YES	NO
1.	Checklist - ANNEXURE – IX		
2.	TENDER COST Rs. 2250/- of DD uploaded as per ANNEXURE-III DD No.....Dated.....issued (name of bank) and delivered to BPPI.		
3.	EMD Rs.100,000/- in the form of DD uploaded as per ANNEXURE-IV DD No.....Dated.....issued by (name of bank) and delivered to BPPI. Uploaded NSIC certificate for exemption if any.		
4.	Documentary evidence for the constitutions of the company / concern		
5.	Scanned copy of License for the Product duly approved by the Licensing Authority for each and every product quoted		
6.	Scanned copy of Import License, if Imported and whole sale Drug license		
7.	The instruments such as power of attorney, Resolution of board etc.,		
8.	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority		
9.	Scanned copy of Market Standing Certificate issued by the Licensing Authority		
10.	Scanned copy of WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate		
11.	Scanned copy of Non Conviction Certificate issued by the licensing authority not older than 6 months.		
12.	Scanned copy of Latest Sales Tax Clearance Certificate/returns filed.		

13.	Scanned copy of Latest income tax assessment orders/returns filed.		
14.	Scanned copy of ANNEXURE-I (Declaration for eligibility in participating the tender) and original Annexure I delivered to BPPI.		
15.	Scanned copy of ANNEXURE –II (Acceptance of Terms and conditions)		
16.	Scanned copy of ANNEXURE –V (Declaration for acceptance of tender conditions and compliance of WHO-GMP) and original Annexure V delivered to BPPI.		
17.	Scanned copy of ANNEXURE -VI (Annual Turnover Statement for three years.) For loan licensee, turnover of host (actual manufacturer) company also needs to be attached.		
18.	Scanned copy of ANNEXURE - VII (Undertaking for embossment of LOGO)		
19.	Scanned copy of ANNEXURE –VII A(Undertaking for embossment of LOGO)		
20.	Scanned copy of ANNEXURE -VIII (Details of Manufacturing Unit)		
21.	Scanned copy of ANNEXURE -IX (List of Items quoted without rates) along with soft copy.		
22.	Scanned copy of ANNEXURE-XI (Notarised Undertaking) and original Annexure XI delivered to BPPI.		
23.	Scanned copy of ANNEXURE—XVI (Mandate form)		

Name and signature of authorised signatory (with company seal)

ANNEXURE -XI

Ref. Clause No. 7.2

NOTORISED UNDERTAKING

(In 20-Rupees Stamp Paper)

I.....,S/o.....,Proprietor/Partner/
Managing Director of(Proprietary Concern/Firm/Company Ltd.)
execute this undertaking for myself and on behalf
of.....(Proprietary Concern/Firm/Company Ltd.).

And whereas, in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

M/s.....

For Self and Firm/Company Ltd.

(Signature and Seal)

Witness:-

(1).....

(2).....

Annexure - XII

Clause 8.1 & 8.2						
Bureau of Pharma Public Sector Undertakings of India, Gurgaon Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)						
(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
1	1105	Zolpidem Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	117000
2	1104	Zoledronic Acid Injections I.P 4mg/ml	5ml	1'sx10	(1'sx10x10)x10	3000
3	1103	Zinc Sulphate 27.45mg, Vitamin A 5000 IU, Vitamin C 50mg, Vitamin E 25 IU, Sodium Selenate 70mcg, Lycopene 5000mcg Capsules	10's	10'sx10	(10'sx10x10)x10	28000
4	1102	Zinc Oxide cream 32% w/w	15gm Tube	1'sx25	(1'sx25)x20	3000
5	1101	Zidovudine 300mg, Lamivudine 150mg, Nevirapine 200mg Tablet I.P	10's	10'sx10	(10x10x10)x5	4000
6	1100	Warfarin Tablets IP 1mg	10's	10'sx10	(10'sx10x10)x20	30000
7	1099	Voglibose 0.3 mg, Metformin 500mg Tablets	10's	10'sx10	(10'sx10x10)x10	49000
8	1098	Voglibose 0.2mg, Metformin 500mg Tablets	10's	10'sx10	(10'sx10x10)x10	37000
9	1097	Vitamin A Capsule 25000 IU	30's	30's x 10	(30's x10)x25	97000
10	1096	Vincristine Injection IP 1mg	1ml	(1ml x10)	(1mlx10x10)x10	3000
11	1095	Vinblastine Injection IP 10mg	10ml	1's x10	(1's x10x10)x10	3000
12	1094	Vildagliptin Tablets 50mg	14's	14'sx10	(14'sx10x10)x10	141000
13	1093	Vildagliptin 50mg, Metformin 500mg Tablets	10's	10'sx10	(10'sx10x10)x5	288000
14	1092	Venlafaxine Hydrochloride ER Tablets 75mg	10's	10'sx10	(10'sx10x10)x20	7000
15	1091	Vecuronium Bromide Injection I.P 4mg	Vial	1x10	(1x10)x100	6000
16	1090	Valproic Acid Tablets I.P 250mg	10's	10'sx10	(10'sx10x10)x10	3000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
17	1089	Ubidecarenone (Ubiquinone-10/Coenzyme Q10) Tablets 100mg	10's	10'sx10	(10'sx10x10)x10	9000
18	1088	Trimetazidine Tablets 35mg	10's	10'sx10	(10'sx10x10)x20	10000
19	1087	Trihexyphenidyl Hydrochloride Tablets 2mg	10's	10'sx10	(10'sx10x10)x20	124000
20	1086	Torsemide Injection 10mg	2ml	(2ml x10)	(2mlx10x10)x10	83000
21	1085	Topiramide Tablets I.P 25mg	10's	10'sx10	(10'sx10x10)x10	47000
22	1084	Tolvaptan Tablets 15mg	4's	4's x10	(4'sx10x10)x20	8000
23	1083	Tolterodine Tablets 2mg	10's	10'sx10	(10'sx10x10)x20	14000
24	1082	Tolperisone Hydrochloride SR Tablets 450mg	10's	10'sx10	(10'sx10x10)x10	14000
25	1081	Tizanidine Tablets I.P 2mg	10's	10'sx10	(10'sx10x10)x20	19000
26	1080	Ticagrelor Tablets 90mg	14's	14'sx10	(14'sx10x10)x10	44000
27	1079	Testosterone Propionate Injection I.P 25 mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	34000
28	1078	Terpin Hydrate 10mg, Dextromethorphan HBr. 10mg, Methol 3.75mg/5ml Syrup	50ml	1's x10	(1's x10)x10	3000
29	1077	Terbutaline Sulphate Injection 0.5mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	3000
30	1076	Tenofovir Tablets 300mg	10's	10'sx10	(10'sx10x10)x10	7000
31	1075	Teneligliptin Film coated tablets 20mg	10's	10'sx10	(10'sx10x10)x20	49000
32	1074	Telmisartan 80mg, Hydrochlorothiazide 12.5mg Tablets	10's	10'sx10	(10'sx10x10)x20	80000
33	1073	Telmisartan 40mg, Metoprolol 25mg Tablets	10's	10'sx10	(10'sx10x10)x20	15000
34	1072	Tamsulosin Modified-Release Capsules 0.4 mg	10's	10'sx10	(10'sx10x10)x20	8000
35	1071	Tacrolimus Capsules 1mg	10's	10'sx10	(10'sx10x10)x20	19000
36	1070	Sulphur 10% w/w Cream/Oint/Gel	20gm	1's x10	(1's x10)x50	3000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
37	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	10ml	1's x10	(1's x10)x100	20000
38	1068	Sucralfate 1gm With Oxetacain 10mg/10ml Suspension	100ml	1's x10	(1's x10)x5	66000
39	1067	Streptomycin Sulphate Injection I.P 1000mg	Vial	1x10	(1x10)x50	251000
40	1066	Spironolactone Tablets I.P 100mg	15's	15x10	(15x10x10)x10	31000
41	1065	Spironolactone 50mg, Torasemide 5mg Tablets	10's	10'sx10	(10'sx10x10)x20	69000
42	1064	Spironolactone 50mg, Torasemide 10mg Tablets	10's	10'sx10	(10'sx10x10)x20	62000
43	1063	Sparfloxacin Tablets 250mg	10's	10'sx10	(10'sx10x10)x10	3000
44	1062	Sofosbuvir Tablets 400mg	10's	10'sx10	(10'sx10x10)x10	3000
45	1061	Sodium Valproate(Divalproex Sodium) Syrup 200 Mg/5ml	200ml	1's x10	(1's x10)x5	11000
46	1060	Sodium Valproate Tablets 300mg	10's	10'sx10	(10'sx10x10)x10	19000
47	1059	Sodium Valproate EC Tablets I.P 200mg	10's	10'sx10	(10x10x10)x10	134000
48	1058	Sodium Bicarbonate Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	16000
49	1057	Sitagliptin 50mg, Metformin 500mg Tablets	10's	10'sx10	(10x10x10)x5	139000
50	1056	Sitagliptin 50mg, Metformin 1000mg Tablets	10's	10'sx10	(10x10x10)x5	31000
51	1055	Sirolimus (Rapamycin) Tablets 1mg	10's	10'sx10	(10'sx10x10)x20	3000
52	1054	Silymarin 70 mg, L-Ornithine L- Aspartate 250mg Tablets	10's	10'sx10	(10'sx10x10)x20	4000
53	1053	Sevelamer Tablets 400mg	10's	10'sx10	(10'sx10x10)x10	29000
54	1052	Sevelamer Tablet 800mmg	10's	10'sx10	(10x10x10)x5	7000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
55	1051	Sertraline Tablets I.P 25mg	10's	10'sx10	(10'sx10x10)x20	42000
56	1050	Sertraline Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x20	18000
57	1049	Sertraline Tablets 50mg	10's	10'sx10	(10'sx10x10)x20	50000
58	1048	Saxagliptin Tablets 5mg	14's	14'sx10	(14'sx10x10)x10	37000
59	1047	Saroglitazar Tablets 4mg	10's	10'sx10	(10'sx10x10)x20	43000
60	1046	Salmeterol 50 Mcg, Fluticasone Propionate 250 Mcg/1 Dose Multihaler Mdi	120mdi	1's x 10	(1's x 10)x100	6000
61	1045	S-Adenosyl-L-Methionine Tablet 400mg	10's	10'sx10	(10'sx10x10)x10	14000
62	1044	Rosuvastatin Tablet I.P 5mg	10's	10'sx10	(10'sx10x10)x20	105000
63	1043	Ritonavir Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x20	3000
64	1042	Risperidone Tablets 4mg	10's	10'sx10	(10'sx10x10)x20	11000
65	1041	Risperidone 4mg, Trihexiphenidyl 2mg Tab.	10's	10'sx10	(10'sx10x10)x20	22000
66	1040	Rifaximin Tablets 400mg	10's	10'sx10	(10'sx10x10)x20	54000
67	1039	Repaglinide Tablets I.P 1mg	10's	10'sx10	(10'sx10x10)x20	28000
68	1038	Recombinant Human Erythropoietin Injection 2000 IU	Vial	1x10	(1x10)x100	3000
69	1037	Recombinant Human Erythropoietin Inj. 4000 IU	Vial	1x10	(1x10)x100	3000
70	1036	Ranolazine Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	115000
71	1035	Ramipril 5mg, Metoprolol 50mg Tablets	10's	10'sx10	(10'sx10x10)x20	27000
72	1034	Raloxifene HCl Tablets 60mg	10's	10'sx10	(10'sx10x10)x20	5000
73	1033	Racecadotril Sachet I.P 10mg	10's	10'sx10	(10'sx10x10)x20	72000
74	1032	Quetiapine Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x20	34000
75	1031	Quetiapine Fumarate Tablets I.P 200mg	10's	10'sx10	(10'sx10x10)x20	12000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
76	1030	Primethamine 25 mg, Sulfadoxine 500mg Tablets I.P	2's	2 x 10	(2x10x10)x10	12000
77	1029	Pyrazinamide Tablets I.P 1000mg	10's	10'sx10	(10'sx10x10)x5	20000
78	1028	Pyenogenol Tablets 25mg	10's	10'sx10	(10'sx10x10)x20	3000
79	1027	Prulifoxacin Tablets 600mg	5's	5's x10	(5's x10x10)x20	21000
80	1026	Propranolol Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	270000
81	1025	Propranolol Injection I.P 1mg	1ml	(1ml x10)	(1mlx10x10)x10	3000
82	1024	Promethazine Injection I.P 25 mg/ml	2ml	(2ml x10)	(2mlx10x10)x10	371000
83	1023	Progesterone Inj. I.P 100mg	1's	1'sx 10	(1'sx10x10)x10	3000
84	1022	Prochlorperazine Maleate Tablets I.P 5mg	10's	10'sx10	(10'sx10x10)x20	514000
85	1021	Primaquine Phosphate Tablets 2.5mg	10's	10'sx10	(10'sx10x10)x20	4000
86	1020	Prazosin Tablets 10mg	10's	10'sx10	(10'sx10x10)x20	50000
87	1019	Praziquantel Tablets 600mg	10's	10'sx10	(10x10x10)x5	3000
88	1018	Pramipexole Dihydrochloride Monohydrate Tablets 0.5mg	10's	10'sx10	(10'sx10x10)x20	32000
89	1017	Pralidoxime Chloride Injection I.P 500mg	Vial	1x10	(1x10)x100	3000
90	1016	Povidone 6mg, Polyvinyl Alcohol Eye Drops 14 Mg/1ml	5ml	5ml x 10	(5ml x25)x20	3000
91	1015	Potassium Nitrate 5 % w/w, Sodium Monofluorophosphate 0.7 % w/w, Triclosan 0.3 % w/w Tooth Paste	50gm	1 x 10	(1 x 10)x20	34000
92	1014	Potassium Chloride Tablets 600mg	6's	6'sx10	(6'sx10x10)x10	3000
93	1013	Potassium Chloride 500mg/5ml Syrup	200ml	1's x10	(1's x10)x5	3000
94	1012	Piracetam Tablets 400mg	10's	10'sx10	(10'sx10x10)x10	5000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
95	1011	Piracetam Syrup 500mg/5ml	100ml	1's x10	(1's x10)x5	14000
96	1010	Piperazine Citrate Syrup I.P 750mg/5ml	30ml	1's x10	(1's x10)x20	5000
97	1009	Pioglitazone Tablet I.P 15mg	10's	10'sx10	(10'sx10x10)x20	73000
98	1008	Phytomenadione (Vitamin K1) Injection 1 mg/0.5ml	0.5ml Ampoule	(0.5ml x10)	(0.5mlx10x10)x10	51000
99	1007	Phenylephrine Injection I.P 10mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	3000
100	1006	Phenylephrine 2.5%w/v Eye Drop	5ml	1 x 25	(1 x 25)x20	3000
101	1005	Phenobarbitone Tablets I.P 30mg	30's	30's x 10	(30's x10)x25	58000
102	1004	Pethidine Injection I.P 50mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	3000
103	1003	Permethrin Cream 5% w/w	30gm	1's x10	(1's x10)x25	27000
104	1002	Pentoxifyverine Citrate Tablets 400mg	10's	10'sx10	(10'sx10x10)x10	3000
105	1001	Penicillamine Tablets I.P 250 mg	10's	10'sx10	(10'sx10x10)x20	6000
106	1000	Paroxetine Tablets I.P 12.5mg	10's	10'sx10	(10'sx10x10)x20	29000
107	999	Paroxetine SR Tablet 37.5mg	10's	10'sx10	(10'sx10x10)x20	4000
108	998	Paracetamol 100mg/ml Infant Drops	15ml	1's x10	(1's x10)x100	132000
109	997	Paclitaxel Injection 100mg	Vial	1x10	(1x10)x100	3000
110	996	Oxcarbazepine Tablets I.P 300mg	10's	10'sx10	(10'sx10x10)x20	149000
111	995	Oxazepam Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	10000
112	994	Oxaliplatin Injections 50mg	Vial	1x10	(1x10)x100	3000
113	993	Ondansetron Oral Solution I.P 2 mg/5ml	30ml	1's x10	(1's x10)x20	234000
114	992	Olmesartan Tablets 20mg	10's	10'sx10	(10'sx10x10)x20	94000
115	991	Olanzapine Tablets I.P 5mg	10's	10'sx10	(10'sx10x10)x20	98000
116	990	Olanzapine Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	50000
117	989	Nystatin Pessary I.P 1,00,000 Unit	1's	1 x 10	(1x10x10)x10	3000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
118	988	Norgestrel 300 mcg, Ethinyl Estradiol 30 mcg Tablets I.P	28's	28's x 10	(28's x10x10)x10	206000
119	987	Nitrofurantoin Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x20	53000
120	986	Nitrazepam Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	117000
121	985	Nitazoxanide Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	3000
122	984	Nifedipine Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	53000
123	983	Nicotinic Acid (Niacin) Tablets I.P 375mg	10's	10'sx10	(10'sx10x10)x20	3000
124	982	Nicotinic Acid (Niacin) Tablets I.P 100mg	10's	10'sx10	(10'sx10x10)x20	16000
125	981	Nicorandil Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	20000
126	980	Nicorandil PR Tablets I.P 10mg	10's	10'sx10	(10'sx10x10)x20	20000
127	979	Nevirapine Tablets I.P 200mg	10's	10'sx10	(10'sx10x10)x20	3000
128	978	Nepafenac 0.1% w/v Eye Drop	5ml	1 x 25	(1x25)x20	27000
129	977	Nelfinavir Tablets I.P. 250mg	10's	10'sx10	(10'sx10x10)x20	3000
130	976	Nebivolol Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	6000
131	975	Nebivolol 5 mg, Hydrochlorothiazide 12.5 mg Tab.	10's	10'sx10	(10'sx10x10)x20	32000
132	974	Natural Micronised Progesterone Capsules 100mg	10's	10'sx10	(10'sx10x10)x20	86000
133	973	Naloxone Injection I.P 400mcg	1ml	(1ml x10)	(1mlx10x10)x10	3000
134	972	Mycophenolic Acid 500mg Tab.	10's	10'sx10	(10'sx10x10)x10	9000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
135	971	Multi Vitamin Infusion (M.V.I.) Each Vial 5ml Vial 1: Each MI Contain: Ascorbic Acid 20 Mg, Vitamin A 660 Iu, Vitamin D 40 Iu, Thiamine (As Hcl) 0.6 Mg, Riboflavin (As Phosphate) 0.72 Mg, Pyridoxine Hcl 0.8 Mg, Niacinamide 8 Mg, D-Pantothenic Acid (As D-Panthenol) 3 Mg And Vitamin E 2.0 Iu. Nonmedicinal Ingredients: Alkali Oil, Gentisic Acid Ethanolamide, Polysorbate 80, Propylene Glycol And Water For Injection. Vial 2: Each MI Contain: Biotin 12 µg, Folic Acid 0.08 Mg And Vitamin B12 1 µg. Nonmedicinal Ingredients: Alkali Oil, Citric Acid, Propylene Glycol, Sodium Citrate And Water For Injection. 1Dose of 10ml	1 Kit	1x10	(1x10)x100	15000
136	970	Moxonidine Tablets 0.2mg	10's	10'sx10	(10'sx10x10)x20	46000
137	969	Morphine Sulphate Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	3000
138	968	Mirtazapine Tablets 15mg	10's	10'sx10	(10'sx10x10)x20	50000
139	967	Midazolam Tablets 15mg	10's	10'sx10	(10'sx10x10)x20	3000
140	966	Midazolam Injection IP 1mg/ml	5ml	1x10	(1x10x10)x10	44000
141	965	Miconazole 2% w/w Fluocinolone Acetonide-0.01% w/w Ointment 15g	15g	1's x10	(1's x10)x 50	184000
142	964	Methylprednisolone Tablets IP 16mg	10's	10'sx10	(10'sx10x10)x20	26000
143	963	Methyldopa Tablets IP 250mg	10's	10'sx10	(10'sx10x10)x20	48000
144	962	Methylcobalamine Tablets 1500mcg	10's	10'sx10	(10'sx10x10)x20	68000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
145	961	Methotrexate Tablets 5mg	10's	10'sx10	(10'sx10x10)x20	12000
146	960	Metformin SR Tablets IP 850mg	10's	10'sx10	(10x10x10)x5	56000
147	959	Metformin Hydrochloride (ER) 500mg, Saxagliptin 5mg Tablets	10's	10'sx10	(10x10x10)x5	28000
148	958	Mesalazine (Mesalamine) 800mg Tablets	10's	10'sx10	(10x10x10)x5	42000
149	957	Memantine Hydrochloride 10mg Tablets	10's	10'sx10	(10'sx10x10)x20	28000
150	956	Mefloquine HCl Tablets IP 250mg	4's	4's x10	(4'sx10x10)x20	14000
151	955	Mefenamic Acid 50mg, Paracetamol 125mg/5ml Suspension	60ml	1's x10	(1's x10)x10	115000
152	954	Medroxy Progesterone Acetate Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	92000
153	953	Magnesium Sulphate Injections IP 50% w/v	2ml	(2ml x10)	(2mlx10x10)x10	9000
154	952	Lymecycline Capsules BP 408mg	10's	10'sx10	(10'sx10x10)x10	3000
155	951	Lycopene 1000 Mcg, Vitamin A Palmitate 2500 Iu, Vitamin E Acetate 10 Iu, Selenium 35 Mcg, Vitamin C 50 Mg, Zinc Gluconate 3 Mg, Manganese Gluconate 2 Mg, Iodine 100 Mcg, Copper 500 Mcg, Thiamine Hydrochloride 2 Mg, Riboflavin 3 Mg, Pyridoxine Hydrochloride 1.5 Mg Syrup	200ml	1's x10	(1's x10)x5	10000
156	950	Lornoxicam 325mg, Paracetamol 325mg Tablets	10's	10'sx10	(10'sx10x10)x5	7000
157	949	Lorazepam Tablets IP 2mg	10's	10'sx10	(10'sx10x10)x20	105000
158	948	Lorazepam Tablets IP 1mg	10's	10'sx10	(10'sx10x10)x20	38000
159	947	Lithium Carbamate PR Tablets IP	10's	10'sx10	(10'sx10x10)x10	28000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
		450mg				
160	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	20g	1's x10	(1's x10)x50	40000
161	945	Levosulpiride Tablets 25mg	10's	10'sx10	(10'sx10x10)x20	106000
162	944	Levosulbutamol HCl (Levalbuterol) Inhalation solution 50 mcg/MDI	200 Mdi	1's x 10	(1's x 10)x100	34000
163	943	Levosulbutamol 100mcg, Ipratropium Bromide 40mcg Rotacap	30's	30's x 10	(30's x10)x50	161000
164	942	Levofloxacin 250mg, Ornidazole 500mg Tab	10's	10'sx10	(10x10x10)x5	42000
165	941	Levofloxacin 125mg, Ornidazole Suspension 125mg/5ml	30ml	1's x10	(1's x10)x20	3000
166	940	Levodopa Tablets IP 500mg	10's	10'sx10	(10'sx10x10)x10	3000
167	939	Levocarnitine Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	34000
168	938	Levocarnitine Injections 1gm	5ml	5ml x 10	(5ml x 10) x 100	13000
169	937	Levetiracetam Syrup 100 Mg/5ml	100ml	1's x10	(1's x10)x5	10000
170	936	Leuprolide Acetate Injections 3.75mg	1's	1's x 10	(1'sx10x10)x10	3000
171	935	Letrozole Tablets 2.5mg	10's	10'sx10	(10'sx10x10)x20	11000
172	934	Lenalidomide Capsules 10mg	10's	10'sx10	(10'sx10x10)x20	3000
173	933	Leflunomide Tablets IP 20mg	10's	10'sx10	(10'sx10x10)x20	15000
174	932	Latanoprost Eye Drops 0.005%w/v (50mcg/ml)	2.5ml	(2.5ml x 10)	(2.5mlx10)x100	10000
175	931	Lamotrigine Prolong Release Tablets IP 100mg	10's	10'sx10	(10'sx10x10)x20	20000
176	930	Lamotrigine Dispersible Tablets IP 25mg	10's	10'sx10	(10'sx10x10)x20	4000
177	929	Lamivudine 150mg, Stavudine 30mg	10's	10'sx10	(10'sx10x10)x20	3000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
		Tablets				
178	928	Lacosamide (Erlasamide) 100mg Tablet	10's	10'sx10	(10'sx10x10)x20	23000
179	927	L- Ornithine 150mg + Pancreatin 100mg Tablets	10's	10'sx10	(10'sx10x10)x20	40000
180	926	Ketoconazole Cream 2% w/w	15gm Tube	1 x 25	(1 x 25) x 20	13000
181	925	Ivabradine Tablets 5mg	10's	10'sx10	(10'sx10x10)x20	97000
182	924	Isoxsuprine HCl Tablets 10mg	50Tablets	50'sx4	(50'sx4x10)x10	32000
183	923	Isosorbide mononitrate Tablets IP 20mg	10's	10'sx10	(10'sx10x10)x20	98000
184	922	Isopropyl Alcohol (70%) (Spirit)	100ml	1's x10	(1's x10)x5	5000
185	921	Ipratropium Bromide Inhalation IP 20mcg/Meter Dose	200 Mdi	1's x 10	(1's x 10)x100	4000
186	920	Insulin Regular (R-DNA Origin) Injection 100 IU	3ml Disposable Pen	1 x 10	(1 x10x10)x10	3000
187	919	Insulin Aspart (R-DNA Origin) Injection IP 100 IU/ML, 3ml Cartridges	1's	1's x10	(1's x10x10)x10	3000
188	918	Indinavir Injections 400mg	10ml	1's x10	(1's x10x10)x5	3000
189	917	Imipramine HCl Tablets 25mg	10's	10'sx10	(10'sx10x10)x20	77000
190	916	Imatinib mesylate Tablets IP 400mg	10's	10'sx10	(10'sx10x10)x10	3000
191	915	Hydroxyzine HCl Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	32000
192	914	Hydrogen Peroxide IP 6%	100ml	1's x10	(1's x10)x5	3000
193	913	Hydrocortisone Sodium Succinate Injection IP 100mg	Vial	1x10	(1x10)x100	35000
194	912	Hydrochlorothiazide Tablets 12.5mg	10's	10'sx10	(10'sx10x10)x20	98000
195	911	Human Menopausal Gonadotrophin Injection 75 IU with solvent	Vial and solvent	1'sx10	(1'sx10)x100	5000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
196	910	Human Chorionic Gonadotrophin 5000 IU Powder For Inj. With solvent	Vial and solvent	1'sx10	(1'sx10)x100	32000
197	909	Human Albumin IV Injection 20%	50ml	1's x10	(1's x10)x10	3000
198	908	Homatropine HBr Eye Drops IP 2% w/v	3ml	(3ml x10)	(3mlx10)x100	55000
199	907	Haemocoagulase Injection 0.2 IU/ml	10ml	1's x10	(1's x10x10)x10	11000
200	906	Glyceryl Trinitrate Tablets IP 600mcg (Nitroglycerin Tablets)	10's	10'sx10	(10'sx10x10)x20	3000
201	905	Glimepiride 2mg, Metformin Hydrochloride 1g Tablets	10's	10'sx10	(10'sx10x10)x5	162000
202	904	Glimepiride 1mg Metformin 500mg Tablets	10's	10'sx10	(10'sx10x10)x10	323000
203	903	Glimepiride 0.5mg, Metformin Hydrochloride 500mg Tablets	10's	10'sx10	(10'sx10x10)x10	201000
204	902	Gentian Violet 1%w/v Topical Solution	15ml	1's x10	(1's x10)x 50	3000
205	901	Gabapentin Capsules USP 300mg	10's	10'sx10	(10'sx10x10)x20	45000
206	900	Gabapentin 100mg Methylcobalamine 500mcg Tablets	10's	10'sx10	(10'sx10x10)x20	50000
207	899	Frusumide (Furosemide) 20mg, Spironolactone 50mg Tablets	10's	10'sx10	(10'sx10x10)x20	417000
208	898	Framycetin Sulphate Cream 0.5%W/W	20gm	1's x10	(1's x10)x 50	519000
209	897	Formoterol Fumerate 6mcg, Fluticasone Propionate 250mcg Inhaler	120 Mdi	1's x 10	(1's x 10)x100	7000
210	896	Flutamide Tablets IP 250mg	10's	10'sx10	(10'sx10x10)x10	3000
211	895	Fluphenazine HCl Injection 25mg/1ml	1ml	(1ml x10)	(1mlx10x10)x10	8000
212	894	Fluoxetine Capsules 40mg	10's	10'sx10	(10'sx10x10)x20	14000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
213	893	Filgrastim 300mcg/1ml Prefilled Syringe	1's	1 x 10	(1x10x10)x10	10000
214	892	Fentanyl Citrate Injection IP 50mcg/ml	10ml	1's x10	(1's x10x10)x10	3000
215	891	Fenofibrate Capsule 200mg	10's	10'sx10	(10'sx10x10)x20	15000
216	890	Felodipine Prolong Release Tablets 5mg	10's	10'sx10	(10'sx10x10)x20	5000
217	889	Febuxostat Tablets 80mg	10's	10'sx10	(10'sx10x10)x20	16000
218	888	Febuxostat Tablets 40mg	10's	10'sx10	(10'sx10x10)x20	107000
219	887	Ethinylestradiol Tablets IP 20mcg	30's	30's x 10	(30's x10)x25	3000
220	886	Ethinylestradiol 35mcg, Norethindrone 0.5mg, 0.75mg, 1mg Kit	1 Kit	1 kit x10	(1 kit x10x10)x10	3000
221	885	Ethinylestradiol 0.05mg, Levonorgestrel-0.25mg Tablets	21's	21's x10	(21's x 10x10)x10	53000
222	884	Erythromycin Estolate Suspension 125 Mg/5ml	60ml	60mlx10	(60mlx10)x10	21000
223	883	Epinephrine Injection 1 mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	38000
224	882	Efavirenz Tablets IP 600mg	30's	30's x 10	(30's x10)x25	3000
225	881	Ebastine Film Coated Tablets 10mg	10's	10'sx10	(10'sx10x10)x20	40000
226	880	Duloxetine Hydrochloride Capsules 20mg	10's	10'sx10	(10'sx10x10)x20	32000
227	879	Drotaverine HCl Tablets IP 40mg	10's	10'sx10	(10'sx10x10)x20	61000
228	878	Drotaverine HCl 80mg, Mefenamic Acid 250mg Tablets	10's	10'sx10	(10'sx10x10)x20	87000
229	877	Doxazosin Tablets 2mg	10's	10'sx10	(10'sx10x10)x20	6000
230	876	Dorzolamide 2% W/V, Timolol Maleate 0.5% W/V Ear Drops	5ml	5mlx25	(5ml x25)x 20	19000
231	875	Donepezil Hydrochloride Tablets IP	10's	10'sx10	(10'sx10x10)x20	16000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
		10mg				
232	874	Divalproex Sodium GR Tablets IP 500mg	10's	10'sx10	(10'sx10x10)x10	55000
233	873	Divalproex Sodium GR Tablets IP 250mg	10's	10'sx10	(10'sx10x10)x20	49000
234	872	Diphenhydramine HCl Capsules IP 25mg	10's	10'sx10	(10'sx10x10)x20	47000
235	871	Diloxanide Furoate Tablets IP 500mg	10's	10'sx10	(10'sx10x10)x10	5000
236	870	Diethylcarbamazine Citrate Syrup 120mg/5ml	100ml	1's x10	(1's x10)x10	7000
237	869	Didanosine Tablets IP 100mg	10's	10'sx10	(10'sx10x10)x20	3000
238	868	Dicyclomine HCl (Dicycloverine) Injection IP 10mg/ml	2ml	(2ml x10)	(2mlx10x10)x10	68000
239	867	Diclofenac Sodium Suppositories 100mg	5's	5's x10	(5's x10x10)x10	10000
240	866	Diazepam Injection IP 5mg/ml	2ml	(2ml x10)	(2mlx10x10)x10	17000
241	865	Diacerein Capsules IP 50mg	10's	10'sx10	(10'sx10x10)x20	22000
242	864	Dextrose Injection IP 25% w/v	100ml	1's x10	(1's x10)x10	30000
243	863	Dextrose Injection IP 25%	25ml	1's x10	(1's x10)x 40	30000
244	862	Dextromethorphan Tablet 10mg	10's	10'sx10	(10'sx10x10)x20	3000
245	861	Dextromethorphan Lozenges 5mg	6's	6'sx10	(6'sx10x10)x10	72000
246	860	Dextromethorphan HBr Syrup IP 13.5mg/5ml	50ml	1's x10	(1's x10)x10	63000
247	859	Dextran 70 IV Infusion IP	500ml	1's	1's x25	3000
248	858	Dextran 40 IV Infusion IP	500ml	1's	1's x25	3000
249	857	Dexchlorpheniramine maleate Tablets IP 2mg	10's	10'sx10	(10'sx10x10)x20	97000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
250	856	Dexamethasone Sodium Metasulfobenzoate 0.5mg, Framycetin Sulphate 5mg, Gramicidin 0.05mg. Eye/Ear Drop	5ml	5ml x25	(5ml x25)x20	3000
251	855	Desloratadine Tablets 5mg	10's	10'sx10	(10'sx10x10)x20	29000
252	854	Decitabine Tablets 50mg	10's	10'sx10	(10'sx10x10)x20	3000
253	853	Daunorubicin HCl Injection 20mg	Vial	1x10	(1x10)x100	3000
254	852	Dapsone Gel 5%W/W	20gm	1's x10	(1's x10)x50	6000
255	851	Dacarbazine Injection 200mg	Vial	1x10	(1x10)x50	3000
256	850	Cyclosporin Soft Gelatin Capsules IP 50mg	5's	5's x10	(5's x10x10)x20	5000
257	849	Cyclophosphamide Tablets IP 50mg	10's	10'sx10	(10'sx10x10)x20	44000
258	848	Colchicine Tablets IP 500mcg	10's	10'sx10	(10'sx10x10)x20	57000
259	847	Cod Liver Oil Soft Gelatin Capsules 300mg	10's	10'sx10	(10'sx10x10)x20	3000
260	846	Clozapine Tablets IP 100mg	10's	10'sx10	(10'sx10x10)x20	47000
261	845	Clonidine Hydrochloride Tablets IP 100mcg	10's	10'sx10	(10'sx10x10)x20	449000
262	844	Clonazepam Tablets IP 1mg	10's	10'sx10	(10'sx10x10)x20	37000
263	843	Clomipramine SR Tablets 25mg	10's	10'sx10	(10'sx10x10)x20	25000
264	842	Clofazimine Capsules IP 50mg	10's	10'sx10	(10'sx10x10)x20	50000
265	841	Clobazam Capsules IP 10mg	10's	10'sx10	(10'sx10x10)x20	144000
266	840	Citicoline Tablets 500mg	10's	10'sx10	(10'sx10x10)x10	30000
267	839	Citalopram Hydrobromide Tablets IP 20mg	10's	10'sx10	(10'sx10x10)x20	5000
268	838	Cilostazol Tablets IP 50mg	10's	10'sx10	(10'sx10x10)x20	38000
269	837	Cilnidipine Tablets 20mg	10's	10'sx10	(10'sx10x10)x20	68000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
270	836	Ciclopirox Topical Solution, 8% (Nail Lacquer)	5ml	1 x 10	(1 x 10) x 50	3000
271	835	Chondroitin 400mg Glucosamine Sulphate 500mg Tablets	10's	10'sx10	(10x10x10)x5	57000
272	834	Cholecalciferol (Vitamin D3) Drops 400IU/ml	10ml	1's x10	(1's x10)x100	60000
273	833	Cholecalciferol (Vitamin D3) Drops 800 IU per drops	5ml	1 x 10	(1 x 10) x 100	37000
274	832	Chlorthalidone Tablets 12.5mg	10's	10'sx10	(10'sx10x10)x20	78000
275	831	Chlorpromazine Tablets IP 50mg	10's	10'sx10	(10'sx10x10)x20	35000
276	830	Chlordiazepoxide 10mg+ Trifluoperazine 1mg Tablets	10's	10'sx10	(10'sx10x10)x20	6000
277	829	Chloramphenicol Eye Ointment IP 1% w/w	5 gm	1'sx10	(1'sx10x10)x20	17000
278	828	Chloramphenicol Eye Drops 0.5% w/v	5ml	1 x 10	(1 x 10) x 50	37000
279	827	Charcoal Activated Tablets 250mg	100's in a Bottle	100'sx10	(100'sx10)x25	3000
280	826	Cetrimide Cream IP 0.5% W/W	20gm	1's x10	(1's x10)x 50	3000
281	825	Ceftazidime 250mg with Tazobactam 31.25mg Injections	10ml	1's x10	(1's x10)x100	23000
282	824	Cefixime (Drops) 25mg /ml	10ml	1's x10	(1's x10)x100	23000
283	823	Cefepime Injection IP 250mg	Vial	1x10	(1x10)x100	22000
284	822	Cefazolin Sodium Injection IP 500mg	Vial	1x10	(1x10)x100	19000
285	821	Carvedilol Tablets IP 6.25mg	10's	10'sx10	(10'sx10x10)x20	119000
286	820	Carboprost Tromethamine Injection IP 250 mcg/ml	1ml	(1ml x10)	(1mlx10x10)x10	48000
287	819	Capecitabine Tab I.P 500mg	10's	10'sx10	(10'sx10x10)x10	3000
288	818	Calcium Gluconate Injection I.P 10 %	10ml	1's x5	(1's x5)x100	30000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
289	817	Calcium Carbonate 1250 Mg, Vitamin D3 250 Iu, Magnesium Oxide 40 Mg, Manganese Sulphate 1.8 Mg, Zinc Sulphate 7.5 Mg, Copper Sulphate 1 Mg, Sodium Borate 250 Mcg Film Coated Tablets	10's	10'sx10	(10'sx10x10)x5	5000
290	816	Calcium Acetate Tablets 667mg	10's	10'sx10	(10'sx10x10)x5	20000
291	815	Calcitriol Capsules I.P 0.25mcg	10's	10'sx10	(10'sx10x10)x20	35000
292	814	Cabergoline Tablets I.P 0.5mg	4's	4's x10	(4'sx10x10)x20	33000
293	813	Bupropion SR Tablets 150mg	10's	10'sx10	(10'sx10x10)x10	3000
294	812	Bromocriptine Mesylate Tablets I.P 2.5mg	10's	10'sx10	(10'sx10x10)x20	3000
295	811	Bromfenac Sodium Eye Drop 0.09%	5ml	1x10	(1x 10)x100	22000
296	810	Brimonidine Tartrate Eye Drop 0.1 % w/v	5ml	1x10	(1x 10)x100	15000
297	809	Bortezomib Injection 3.5 mg	Vial	1x10	(1x10)x100	3000
298	808	Bisacodyl Suppository I.P 5mg	5's	5's x10	(5's x10x10)x10	28000
299	807	Biphasic Isophane Insulin Injection I.P 100 Iu/ml (30:70) (30% Soluble Insulin And 70% Isophane Insulin)	3 ml Cartridge	1'sx 10	(1'sx 10) x100	44000
300	806	Bicalutamide Tab I.P 50mg	10's	10'sx10	(10'sx10x10)x20	9000
301	805	Betamethasone Valerate 0.1 % w/v, Chloramphenicol 5 % w/v, Lidocaine Hydrochloride 2 % w/v Ear Drop	5ml	1 x 10	(1 x 10) x 100	32000
302	804	Betamethasone Inj. I.P 4 mg/ml	1ml	(1ml x10)	(1mlx10x10)x10	1754000
303	803	Benzyl Benzoate Application I.P 25% w/w	100ml	1's x10	(1's x10)x10	3000
304	802	Benzocaine 20% w/w Gel	15gm Tube	1 x 25	(1 x25)x20	43000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
305	801	Benzocaine 0.36 % w/w, Cetrimide 6.5 % Aerosol Spray	100gm	1's x10	(1's x10)x10	3000
306	800	Bacitracin Zinc 250 Iu Neomycin 5 Mg, Sulphacetamide Sodium 60 Mg Per 1gm Powder	10gm Powder	1 x10	(1x10)x100	131000
307	799	Atropine Sulphate eye ointment I.P 1% w/w	3gm	1's x 10	(1x10x10)x10	5000
308	798	Atropine Sulphate 1% w/v Eye Drop	5ml	1 x10	(1x10x10)x10	5000
309	797	Atracurium Besilate Injection I.P 25mg/ml	2.5ml	(2.5ml x 10)	(2.5mlx10x10)x10	5000
310	796	Atorvastatin I.P 10mg, Aspirin I.P (EC) 75mg Capsules	10's	10'sx10	(10'sx10x10)x20	100000
311	795	Atorvastatin calcium 10 mg, Aspirin 75 mg, Ramipril 5 mg Capsules	10's	10'sx10	(10'sx10x10)x20	172000
312	794	Atorvastatin 10 mg, Ramipril 5 mg Tablets	10's	10'sx10	(10'sx10x10)x20	10000
313	793	Atenolol Tablets 25 mg	14's	14'sx10	(14'sx10x10)x10	323000
314	792	Atenolol 50mg, Hydrochlorothiazide 12.5mg Tablets	10's	10'sx10	(10'sx10x10)x20	8000
315	791	Atenolol 25 mg, Amlodipine 5 mg Tablets	14's	14'sx10	(14'sx10x10)x10	20000
316	790	Aspirin enteric coated Tablets I.P. 75mg	14's	14'sx10	(14'sx10x10)x10	1253000
317	789	Aspartame Tablets I.P. 18mg	100's in a Bottle	100'sx10	(100'sx10)x25	10000
318	788	Anastrozole Tablets IP 1mg	10's	10'sx10	(10'sx10x10)x20	4000
319	787	Amlodipine(5mg),Hydrochlorothiazide(12.5 mg) Tablets	10's	10'sx10	(10'sx10x10)x20	61000
320	786	Amitriptyline hydrochloride 10mg Tablets I.P	10's	10'sx10	(10'sx10x10)x20	81000
321	785	Amitriptyline hydrochloride 10mg Tablets I.P	10's	10'sx10	(10'sx10x10)x20	81000
322	784	Amisulpride Tablets I.P 50mg	10's	10'sx10	(10'sx10x10)x20	25000
323	783	Ambroxol HCl 60mg, Cetirizine Hcl 5mg Tablets	10's	10'sx10	(10'sx10x10)x20	50000
324	782	Ambroxol 75 mg, Levofloxacin 500 mg Tablets	5's	5's x10	(5's x10x10)x20	11000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
325	781	Alprazolam-0.25 mg, Fluoxetine 20 mg Tablets	10's	10'sx10	(10'sx10x10)x20	24000
326	780	Alprazolam PR Tablets I.P 1mg	10's	10'sx10	(10'sx10x10)x20	22000
327	779	Alpha Lipoic acid 100mg, Vit. D3 1000 IU, Folic acid 1.5mg, Pyridoxine 3mg, Methylcobalamin 1500mcg Tablets	10's	10'sx10	(10'sx10x10)x10	35000
328	778	Alpha lipoic acid 100mg, Methylcobalamin 500 mcg Capsules	10's	10'sx10	(10'sx10x10)x10	35000
329	777	Alpha lipoic acid 100mg, Methylcobalamin 0.75mg, Pregabalin 75mg Capsules	10's	10'sx10	(10'sx10x10)x10	28000
330	776	Alogliptin Tablet 25mg	10's	10'sx10	(10'sx10x10)x20	3000
331	775	Allantoin 2 % w/w, Coal tar 5 % w/v cream	20gm	1's x10	(1's x10)x 50	3000
332	774	Alfuzosin PR Tablet I.P 10mg	10's	10'sx10	(10'sx10x10)x20	17000
333	773	Agomelatine Tablets 25mg	10's	10'sx10	(10'sx10x10)x20	20000
334	772	Adenosine Injection 3mg/ml	2ml	(2ml x10)	(2mlx10x10)x10	3000
335	771	Acriflavine 0.1% w/v in Pure Glycerin	100ml	1's x10	(1's x10)x10	3000
336	770	Acitretin Capsules I.P 25mg	10's	10'sx10	(10'sx10x10)x20	3000
337	769	Acetyl Salicylic Acid (Aspirin)Tablet I.P 325mg	14's	14'sx10	(14'sx10x10)x10	21000
338	768	Acetazolamide Tablets I.P 250mg	10's	10'sx10	(10'sx10x10)x10	25000
339	767	Metformin 1000mg SR + Glimipride 2mg Tablet	10's	10's x10	(10 x 10 x 10)x5	30,000
340	766	L-methylfolate calcium 7.5mg Tablet	10's	10's x10	(10's x10x10)x20	30,000
341	765	Mometasone furoate 0.1% w/v + Terbinafine HCl 1% w/v Topical solution 30ml	30 ml	30ml x 10	(30ml x 10)x20	1,00,000
342	762	Nortriptyline Tablet 25 mg Tablet	10's	10's x10	(10's x10x10)x20	30,000
343	761	Dosulepin Tablet BP 25mg (Dothiepin)	10's	10's x10	(10's x10x10)x20	30,000
344	760	Cyclophosphamide 200 mg injection	2 ml	2ml x 10	2ml x 10 x 50	30,000
345	758	Vidagliptin Tablet 50 mg	10's	10's x10	(10's x10x10)x20	2,00,000

**Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)**

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
346	757	Cefuroxime Injection 1500 mg	10 ml	10ml x 10	(10ml x 10 x 10)x10	50,000
347	756	Paracetamol Injection 100mg	2ml ampoules	2ml x 10	(2ml x 10 x 10) x 10	2,00,000
348	755	1% povidone-iodine medicated gargle	50 ml	50 ml x 10	(50 ml x 10) x 10	50,000
349	752	Clotrimazole 1% 100 gm powder	100 gm Powder	100gm x 10	(100gm x 10) x 10	1,00,000
350	751	Antacid powder 5 g sachets Each 5grams contains: Regular - sodium bicarbonate 2.32g, sodium carbonate 0.50g and citric acid anhydrous 2.18g Lemon - sodium bicarbonate 2.29g, sodium carbonate 0.50g and citric acid anhydrous 2.16g	5gm powder	5gm x 10	(5gm x 10 x 10) x 10	1,00,000
351	750	HYOSCINE BUTYLBROMIDE INJECTION 20 mg/1 mL	1ml ampoule	1ml x 10	(1ml x 10 x 10) x 10	1,00,000
352	749	Cholecalciferol-60000 iu granules	1gm sachet	1gm x 10	(1gm x 10 x 10) x 10	2,00,000
353	745	Flucytosine IP 500mg tab	10's	10's x10	(10 x 10 x 10) x 5	30,000
354	744	Potassium citrate USP 1080 mg ER Tablet	10's	10's x10	(10 x 10 x 10) x 5	20,000
355	743	Cefaclor Oral Suspension IP 125 mg	30 ml	30 ml x10	(10 x 10 x 10) x10	20,000
356	742	Cefaclor Capsules I.P 250 mg	10's	10's x10	(10's x10x10)x10	30,000
357	741	Cefpodoxime Proxetil dispersible tablet 50 mg	10's	10's x10	(10's x10x10)x20	30,000
358	738	Metolazone 5 mg tablet	10's	10's x10	(10's x10x10)x20	50,000
359	737	Idebenone 30 mg tablet	10's	10's x10	(10's x10x10)x20	50,000
360	736	Megeestrol Acetate 40 mg tablet	10's	10's x10	(10's x10x10)x20	50,000
361	735	Misoprostol 25mcg Tablets	10's	10's x10	(10's x10x10)x20	50,000
362	734	Dehydroepiandrosterone 25 mg Capsule	10's	10's x10	(10's x10x10)x20	50,000
363	733	Progesterone 200 mg SR Tablets	10's	10's x10	(10's x10x10)x10	50,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
364	732	Normal Saline (NS) 0.9% w/v	500ml IV fluid plastic container using FFS technology	1's	500ml x 20	10,00,000
365	728	Dextrose with Saline 5% w/v + 0.9% w/v	500ml IV fluid plastic container using FFS technology	1's	500MLX20	10,00,000
366	726	Dextrose 10 %	500ml IV fluid plastic container using FFS technology	1's	500ml x 20	3,00,000
367	725	Dextrose 5 %	500ml IV fluid plastic container using FFS technology	1's	500ml x 20	10,00,000
368	724	Whey Peptide based Enteral nutrition Per 100gm Energy 464 Kcal Protin 18.5gm Fat 17 gm MUFA 1.19Gm PUFA 2.58, Carbs 59.40gm Vit A / D/ E/K/C/B1/ B2/NIACIN/B6/Folic Acid/ Pantothenic Acid / B12/ Biotin/ Minerals and Choline Taurine & Carnitine	200 gm Tin	200gm x 1	(200gm x1 x 50)	3,00,000
369	722	Water for Injection amp polypack	5ml	5 ml x 10	(5 ml x 10 x 10) x 10	20,00,000
370	721	Water for Injection amp polypack	2ml	2 ml x 10	(2 ml x 10 x 10) x 10	10,00,000
371	717	Etodolac tablets 300 USP mg IP	10's	10's x10	(10's x10x10)x10	3,00,000
372	714	Ofloxacin 200mg+Ornidazole 500mg infusion	100 ml	100ml x 10	(100ml x 10) x 10	5,00,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
373	713	Glibenclamide 5mg + MetforminHcl 500 mg tab	10's	10's x10	(10 x 10 x 10) x 5	5,00,000
374	707	Piroxicam Caps IP 10 mg	10's	10's x10	(10's x10x10)x20	5,00,000
375	702	Haloperidol Tablet IP 0.5 mg	10's	10's x10	(10's x10x10)x20	2,00,000
376	701	Pilocarpine eye drop IP 2 %	10 ml Vial	10ml x 10	10ml x 10) x 50	3,00,000
377	700	Ketamine Hydrochloride Injection IP 50 mg/ml	20ml Vial	20 ml x 10	(20 ml x 10) x 50	3,00,000
378	696	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg ,Dexamethasone sodium phosphate IP 1 mg Phenylmercuric nitrate 0.001% Eye drops IP	5 ml	5 ml x 10	(5ml x 10 x 10) x 10	3,00,000
379	695	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg Phenylmercuric nitrate 0.001% Eye drops IP	5 ml	5 ml x 10	(5ml x 10 x 10) x 10	3,00,000
380	693	Tropicamide 1% Eye Drops IP	5 ml	5ml x 10	(5ml x 10 x 10) x 10	3,00,000
381	691	Ofloxacin Eye Drops 0.3% w/v	10 ml	10ml x 10	(10ml x 10) x 50	5,00,000
382	687	Lactulose 10mg/15 ml	200 ml	200ml x 1	(200ml x 1) x 50	5,00,000
383	681	Phenazopyridine Hcl 100mg tab	10's	10's x10	(10's x10x10)x10	5,00,000
384	679	Nalidixic Acid 500 mg Tablet IP	10's	10's x10	(10 x 10 x 10) x 5	5,00,000
385	678	levodopa & Carbidopa tab (250 mg + 25 mg) Tab. IP	10's	10's x10	(10's x10x10)x10	5,00,000
386	677	Flupentixol 0.5 mg Tablet IP	10's	10's x10	(10's x10x10)x20	5,00,000
387	675	Sitagliptin 50 mg Tablet	10's	10's x10	(10's x10x10)x20	2,00,000
388	674	Sitagliptin 100 mg Tablet	10's	10's x10	(10's x10x10)x10	2,00,000
389	673	Biotin 10 mg Tablet	10's	10's x10	(10's x10x10)x20	3,00,000
390	668	Multivitamin Drops : Vitamin A(as Palmitate)IP 2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine Hydrochloride IP 1mg,Riboflavine Sodium Phosphate IP 1.5mg,Niacinamide IP 10mg,D-Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine	15ml	15ml x 10	(15ml x 10) x 50	3,00,000

**Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)**

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
391	665	BCOMPLEX PLUS Each capsule contains - Thiamine mononitrate IP- 10mg, Riboflavin IP -10 mg, Pyridoxine HCl IP-3mg, Vitamin B 12 IP - 5mcg, Niacinamide IP - 50mg, Calcium Pantothenate IP- 12.5mg, Folic Acid IP -1mg, Ascorbic Acid IP- 150mg	10's	10's x10	(10's x10x10)x10	10,00,000
392	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	200ml	200ml x 1	(200ml x 1) x 50	3,00,000
393	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	100ml	100 ml x 10	(100 ml x 10) x 10	3,00,000
394	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin q.s cream/ointment	75gm	75gm x10	(75 gm x 10) x 10	3,00,000
395	657	Hydroquinone 2.0% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w in a cream base q.s	15gm	15 gm x 20	(15gm x 20) x 25	5,00,000
396	654	Enzyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200ml	200ml x 10	(200ml x 10) x 5	5,00,000
397	647	Diclofenac + Menthol 5%+ Oleum 3% + Methyl Salicylate Gel	20gm	20gm x 20	(20gm x 20) x 25	10,00,000
398	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg Tablet	10's	10's x10	(10 x 10 x 10) x 5	10,00,000
399	634	Clobetasol Propionate BP...0.05 % w/w, Neomycin Sulphate IP...0.50 % w/w., Miconazole Nitrate IP...2.00 % w/w, Chlorocresol IP(as preservative) 0.10 % w/w Cream/Ointment	20gm	20gm x 20	(20gm x 20) x 25	2,00,000
400	632	Ethamsylate B.P 250 mg.	10's	10's x10	(10's x10x10)x10	3,00,000
401	631	Ethamsylate B.P 500 mg.	10's	10's x10	(10's x10x10)x10	3,00,000
402	629	Inhalent Softgel Caps. (Camphor 25 mg + Clorothymol 5 mg + Eucalyptol 130 mg + Menthol 55 mg + Terpineol 110 mg	10's	10's x10	(10's x10x10)x10	5,00,000
403	628	Etophylline IP 231mg. + Theophylline 69mg Tablet	10's	10's x10	(10's x10x10)x10	5,00,000
404	627	Etophylline IP 115mg + Theophylline 35mg Tablet	10's	10's x10	(10's x10x10)x10	5,00,000
405	625	Bromhexine Hydrochloride 8mg Phenylephrine Hydrochloride 5mg Cough Tablets	15's	15's x 10	(15's x10x10)x 10	5,00,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
406	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's	8's x 10	(8's x 10 x 10) x 10	10,00,000
407	622	Cough lozenges Ginger / Lemon (2,4 Diclorobenzyl alcohol 1.2 mg + Amylmetacresol 0.6 mg in Ginger /Lemon flavour	8's	8's x 10	(8's x 10 x 10) x 10	10,00,000
408	617	Celecoxib 200 mg capsules	10's	10's x10	(10's x10x10)x10	2,00,000
409	616	Celecoxib 100 mg capsules	10's	10's x10	(10's x10x10)x10	2,00,000
410	609	Silver Nitrate 0.20 % w/w, Chlorhexidine Gluconate Solution 0.20%, Preservative: Chlorocresol 0.12 % w/w, In a Cream Base q.s.	15 gm Tube	15gm x 20	(15gm x 20) x 25	7,50,000
411	607	Beclamethasone Dipropionate..0.025% w/, Neomycin Sxulphate..0.5% w/w (3500 Unit /G) Chlorocresol 0.1% w/w	15gm	15gm x 20	(15gm x 20) x 25	10,00,000
412	605	Etofylline BP 200 mg, Salbutamol Sulphate IP equivalent to Salbutamol .4 mg, Bromhexine Hydrochloride IP 8 mg Tablet	10's	10's x10	(10's x10x10)x10	10,00,000
413	603	Cetirizine Dihydrochloride IP...5 mg., Phenylephrine Hydrochloride IP...10 mg., Paracetamol IP...325 mg.	10s	10's x10	(10's x10x10)x10	10,00,000
414	594	GLUCOSE D POWDER	100gm	100gm x 10	(100gm x 10) x 10	3,00,000
415	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	10's x10	(10's x10x10)x10	3,00,000
416	538	Theophylline PR Tablets IP 400mg	10's	10'sx10	(10'sx10x10)x10	105000
417	534	Beclometasone Dipropionate 100 Mcg, Salbutamol 200 Mcg Rotacap	30's	30's x10	(30's x10)x25	12000
418	532	Fluticasone 250mcg, Salmeterol 50mcg/Rotacap	30 Rotacaps	1's x 10	(1'sx10x10)x10	73000
419	506	LEVO-THYROXINE TABLETS IP 50 MCG IP	100's in Bottle	100's x 10	(100's x 10) x 50	1,00,000
420	505	CARBIMAZOLE TABLETS IP 10mg	100's in Bottle	100's x 10	(100's x 10) x 50	20,000
421	496	Dydrogesterone Tablets IP 10mg	10's	10'sx10	(10'sx10x10)x20	150000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
422	494	ISPAGHULA HUSK IP 100 GM IP	100gm	100gm x 10	(100gm x 10) x 10	2,00,000
423	493	ISPAGHULA HUSK IP 50 GM IP	50gm	50gm x 10	(50gm x 10) x 25	2,00,000
424	492	SULFASALAZINE TABLETS EC BP 500 MG	10's	10's x10	(10's x10x10)x10	2,00,000
425	490	SIMETHICONE 40 MG DROPS	15ml	15ml x 10	(15ml x 10) x 500	1,00,000
426	488	LANSOPRAZOLE CAPSULES IP 15 MG IP	10's	10's x10	(10's x10x10)x20	1,00,000
427	480	LEVOSULPIRIDE 75 MG+ ESOMEPRAZOLE 40 MG CAPSULES	10's	10's x10	(10's x10x10)x10	1,00,000
428	455	VERAPAMIL TABLETS IP 80 MG IP	10's	10's x10	(10's x10x10)x20	1,20,000
429	444	ENALAPRIL 10MG + HYDROCHLORTHIAZIDE 25 MG TABLETS	30's	30's x 10	(30's x10x10)x10	1,00,000
430	442	FENOFIBRATE CAPSULES BP 160 MG IP	10's	10's x10	(10's x10x10)x10	50,000
431	421	NEBIVOLOL TABLETS IP 5 MG	10's	10's x10	(10's x10x10)x20	2,00,000
432	419	HEPARIN SODIUM 50 IU, Benzyl Nicotinate 2 mg/ 1 gm Ointment/Cream	20gm	20gm x 20	20gm x 20 x 25	1,00,000
433	415	GLYCERYL TRINITRATE TABLETS IP 2.6 mg	25's	25's x 10	(25's x10x10) x10	1,00,000
434	412	AZATHIOPRINE TABLETS IP 50 MG	10's	10's x10	(10's x10x10)x20	60,000
435	409	BENZATHINEPENICILLIN INJ IP 1.2 MILLION UNITS IP	Vial	1's x 5	(1 x 5 x 10) x10	2,00,000
436	408	BENZATHINEPENICILLIN INJ IP 0.6 MILLION UNITS IP	Vial	1's x 5	(1 x 5 x 10) x10	2,00,000
437	397	Oxytetracycline Cap I.P 250mg	10's	10'sx10	(10'sx10x10)x20	164000
438	396	AMPHOTERICIN B INJECTION IP. 50MG/ML IP	Vial & wfi	1's x 10	(1 x 10) x 100	20,000
439	394	PYRANTEL PAMOATE ORAL SUSPENSION IP 250 MG/10 ML IP	10 ml	10 ml x 10	(10ml x 10) x 100)	1,00,000
440	392	GRISEOFULVIN TABLETS IP 250 MG IP	10's	10's x10	(10's x10x10)x10	2,00,000
441	389	Penicillin G Pottasium Tablets 400000 U	6's	6'sx10	(6'sx10x10)x20	1076000
442	379	RIFAMPICIN and ISONIAZIDE TABLETS IP (450 MG+300 MG)	10's	10's x10	(10 x 10 x 10) x 5	1,00,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
443	363	Insulin Glargine 100 IU Injections	CARTRI DGE/vial 3 ML	3ml x 10	(3ml x 10 x 10) x 10	72,000
444	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 40 IU/ML (50:50)	10 ml Vial	10ml x 5	(10ml x 5 x 10) x 10	3,40,000
445	352	Bupivacaine Hydrochloride 0.5% w/w Inj. IP	4 ml	4 ml x 5	(4ml x 5 x 10) x 10	20,000
446	345	GENTAMYCIN 0.3% W/V Eye drops IP	5ml	5ml x 10	(5ml x 10 x 10) x10	2,00,000
447	333	DEXAMETHASONE 0.5 MG TABS IP	10's	10's x10	(10's x10x10)x20	5,00,000
448	330	Prednisolone 10 mg Tabs IP	10's	10's x10	(10's x10x10)x20	3,00,000
449	329	PREDNISOLONE TABLETS IP 5 MG IP	15's	15's x 10	(15's x10x10)x 10	3,00,000
450	318	Carbamazepine 200mg Tabs IP	10's	10's x10	(10's x10x10)x10	2,00,000
451	317	Carbamazepine 100mg Tabs IP	10's	10's x10	(10's x10x10)x10	1,00,000
452	283	Isosorbide Dinitrate 10 mg Tabs IP	10's	10's x10	(10's x10x10)x20	3,00,000
453	281	Heparin Sodium 5000iu/ ml Inj. IP	5 ml	5 ml x 10	(5 ml x 10 x 10) x 10	50,000
454	280	Heparin Sodium 1000iu/ ml Inj. IP	5 ml	5 ml x 10	(5 ml x 10 x 10) x 10	50,000
455	274	Dopamine HCl 200 mg/5ml Inj. IP	5 ml	5 ml x 10	(5 ml x 10 x 10) x 10	20,000
456	260	Salbutamol 4mg Tabs IP	10's	10's x10	(10's x10x10)x20	2,00,000
457	259	Salbutamol 2mg /5ml Syrup IP	100 ml bottles	100ml x 10	(100ml x 10) x 10	2,00,000
458	254	Promethazine(5mg/5ml) solution IP	100ml bottles	100ml x 10	(100ml x 10) x 10	1,00,000
459	245	Etophyllin +Theophylline (77 mg + 23 mg) Tabs	10's	10's x10	(10's x10x10)x10	1,00,000
460	244	THEOPHYLLINE 25.3 MG+ ETOPHYLLINE 84.7MG INJECTION /2ML	2ml	2ml x 10	(2mlx10x10) x 10	1,00,000
461	233	Vitamin-C Chewable 500mg Tablet IP	10's	10's x10	(10's x10x10)x10	2,00,000
462	217	Ranitidine HCl. 150 mg film coated Tablets IP	10's	10's x10	(10's x10x10)x10	2,00,000
463	202	METRONIDAZOLE 400 MG Tablet IP	10's	10's x10	(10's x10x10)x10	10,00,000
464	201	METRONIDAZOLE 200 MG FILM COATED Tablet IP	10's	10's x10	(10's x10x10)x10	3,00,000
465	200	Metoclopramide 5mg/ml Inj. IP	2 ml	2 ml x 10	(2 ml x 10 x 10) x 10	50,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
466	195	Ispagula Husk Powder IP	200 gm Pack	200gm x 1	(200gm x 1) x 50	50,000
467	194	HYOSCINE Butylbromide 10 MG tablet IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
468	193	Furazolidone 100 mg Tabs IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
469	179	Albendazole 400mg Tabs IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
470	158	Etoposide Inj. IP 100 mg/5ml	Vial & wfi	1 x 10	(1 x 10) x 100	20,000
471	154	Cisplatin Inj. IP 50 mg	Vial	1 x 6	(1 x 6) x 100	20,000
472	152	Bleomycin Sulphate Inj. IP 15 Units	Vial	1 x 10	(1 x 10) x 100	20,000
473	141	Glipizide 5 mg Tabs IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
474	134	Glibenclamide 5 mg Tabs IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
475	133	Glibenclamide 2.5 mg Tabs IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
476	132	Silver Sulphadiazine 1 % w/w Cream IP	500 gm jars	500 gm x 1	(500 gm x 1) x 20	20,000
477	131	Silver Sulphadiazine 1 % w/w Cream IP	20 gm tubes	20 gm x 25	(20 gm x 25) x 20	1,00,000
478	126	Povidone Iodine 10 % Solution IP	500 ml bottles	500 ml x 1	(500 ml x 1) x 20	20,000
479	124	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/Jar	250 gm x 1	(250 gm x 1) x 25	20,000
480	119	Fluconazole 150 mg Tablets IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
481	111	Application Benzyl Benzoate 25 % w/v Lotion IP	100 ml	100 ml x 10	(100 ml x 10) x 10	50,000
482	94	Gentamycin Sulphate 80 mg/ 2ml Inj. IP	2 ml	2 ml x 20	(2ml x 20 x 10) x 10	2,00,000
483	92	Doxycycline 100 mg Caps IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000
484	91	Co-trimoxazole –SS (80 mg + 400 mg) Tablet IP	10's	10's x 10	(10's x 10 x 10) x 10	1,00,000
485	89	CO-TRIMOXAZOLE TABLETS IP (160 MG + 800 MG)	10's	10's x 10	(10 x 10 x 10) x 5	1,00,000
486	86	Ciprofloxacin 500 mg film coated Tablets IP	10's	10's x 10	(10 x 10 x 10) x 5	1,00,000
487	85	Ciprofloxacin 250 mg film coated Tablets IP	10's	10's x 10	(10's x 10 x 10) x 10	50,000
488	82	Cephalexin 500 mg Caps IP	10's	10's x 10	(10's x 10 x 10) x 10	1,00,000
489	66	Cefpodoxime 200 mg film coated Tablets IP	10's	10's x 10	(10's x 10 x 10) x 10	2,00,000

Bureau of Pharma Public Sector Undertakings of India, Gurgaon
Tender for supply of drugs (Tender No. BPPI/ Drug – 040/2016 dated 09/06/2016)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	Drug Code	Generic name of Drug	Unit Size	Pack size	Packing per Carton (Shipper Pack)	Approx. Tender Quantity
490	64	Cefotaxime Sodium 500 mg Inj. IP	Vial & wfi	10 ml x 10	(10ml x 10) x 500	1,00,000
491	63	Cefotaxime Sodium 250 mg Inj. IP	Vial & wfi	10 ml x 10	(10ml x 10) x 100)	1,00,000
492	62	Cefotaxime Sodium 1000mg Inj. IP	Vial & wfi	10 ml x 10	(10 x 10) x 50	1,00,000
493	52	Cefadroxil 500 mg film coated Tablets IP	10's	10's x10	(10's x10x10)x10	2,00,000
494	50	Azithromycin 500 mg film coated Tablets IP	10's	10's x10	(10's x10x10)x10	2,00,000
495	49	Azithromycin 250 mg film coated Tablets IP	10's	10's x10	(10's x10x10)x10	1,00,000
496	48	Azithromycin 100 mg Dispersible Tab	10's	10's x10	(10's x10x10)x10	1,00,000
497	47	Azithromycin (100mg/ 5ml) Suspension IP	15 ml bottles	15ml x 10	(15 ml x 10 x 50)	1,50,000
498	45	Amoxycillin 500 mg Caps IP	10's	10's x10	(10's x10x10)x10	1,50,000
499	44	Amoxycillin 250 mg Caps IP	10's	10's x10	(10's x10x10)x10	2,00,000
500	43	Amoxycillin 125mg/ 5ml Powder for Suspension IP	60 ml bottles	60 ml x 10	(60ml x 10 x 50)	1,00,000
501	39	Amoxycillin + Clavulanic acid (500 mg + 125 mg) film coated Tablets IP	6's	6's x 10	(6's x 10 x 10) x10	5,00,000
502	24	Pentazocine 30 mg/ ml Inj. IP	1 ml	1 ml x 10	(1ml x 10 x 10) x10	3,00,000
503	17	Indomethacin Capsules IP 75mg	10's	10's x10	(10's x10x10)x20	1,00,000
504	16	Ibuprofen Tablets IP 400mg	15's	15's x 10	(15's x10x10)x 10	5,00,000
505	15	Ibuprofen film coated Tablets IP 200mg	10's	10's x10	(10's x10x10)x10	2,00,000
506	14	Ibuprofen 400mg + Paracetamol 325mg Tablets	15's	15's x 10	(15's x10x10)x 5	5,00,000
507	9	Diclofenac Sodium (SR) Tablets IP 100 mg	10's	10's x10	(10's x10x10)x10	3,00,000

ANNEXURE -XIII

Ref. Clause No.10.1

Performance Security Bank Guarantee

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

WHEREAS.....(Name of the Supplier) herein called “the Supplier” has undertaken, in pursuance of Tender **BPPI/DRUG-040/2016 Dtd. 09-06-2016** to supply of **Drugs and Medicines for the year 2016-18**, (Description of Goods and Services) hereinafter called “the Contract”.

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier’s performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Supplier a Guarantee

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, upto a total of(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until theday of.....2018.

Signature and Seal of Guarantors

.....
.....
.....

Date.....2016

Address.....

.....

ANNEXURE-XIV

Ref. Clause No.10.2

AGREEMENT

THIS AGREEMENT made theday of2016 Between Bureau of Pharma Public Sector Undertakings of India, IDPL Complex, Old-Delhi Gurgaon Road, Dundahera, Gurgaon 122016 (Haryana)

(Name of purchaser) of (Country of Purchaser) (here in after “the Purchaser”) of the one part and(Name of Supplier) of(City and Country of Supplier) (herein after called “the Supplier”) of the other part :

WHEREAS the Purchaser is desirous that certain Goods and ancillary services viz; Supply of Drugs and Medicines in the tender Reference No. BPPI/DRUG-040/2016 (Brief Description of Goods and Services) and has accepted a bid by the Supplier for the supply of those goods and services for the sum of(Contract Price in Words and Figures(hereinafter called “the Contract Price”).

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to, and they shall be deemed to form and be read and construed as part of this agreement.
2. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz
 - a. The Letter of Acceptance issued by the purchaser.
 - b. The Notice Inviting Tender
 - c. The supplier’s bid including enclosures, annexures, etc.
 - d. The Terms and Conditions of the Contract
 - e. The Schedule of Requirement
 - f. The Technical Specification

- g. Any other document listed in the supplier's bid and replies to queries, clarifications issued by the purchaser, such confirmations given by the bidder which are acceptable to the purchaser and the entire Addendum issued as forming part of the Contract.
3. In consideration of the payments to be made by the Purchaser to the Supplier as hereinafter mentioned, the Supplier hereby covenants with the Purchaser to provide, the goods and services and to remedy defects therein in conformity in all respects with the provisions of the Contract. .
4. The purchaser hereby covenants to pay the Supplier in consideration of the provision of the goods and services and the remedying of defects therein, the Contract Price or such other sum as may become payable under the provisions of the Contract at the times and in the manner prescribed by the Contract.

Brief particulars of the goods and services which shall be supplied / provided by the Supplier are as under:

S.No.	Drug Code	Name of Product	UNIT	Tender Qty in Unit* (A)	Unit Price (B)	CST against form C/VAT in % (C)	Total (B+C) (D)	Total value inclusive CST/VAT (A x D)
Total Contract Value								

- * **Tender quantity indicated here is tentative and may vary subjected to various terms and conditions of the tender.**
- * **Excise duty as applicable on MRP to be intimated by BPPI at the time of placing orders will be payable as per prevailing excise duty rates.**

DELIVERY SCHEDULE

Supply shall all complete within 60th day from the date of issue of Ist purchase order and within 45th day from the date of issue of subsequent purchase order.

Dispute Resolution

This agreement shall be deemed to have been made/ executed at Delhi for all purpose.

Normally, there should not be any scope of dispute between the BPPI and the _____ after entering into a mutually agreed valid contract/agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/agreement leading to disagreement BPPI and the _____ shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the _____ shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be full and final which shall be binding on both the parties.

Governing Law/Jurisdiction

The applicable law governing this agreement shall be the laws of India and the court of Delhi shall have the exclusive jurisdiction to try any dispute arising out of the violation of any terms and condition of this agreement.

IN WITNESS where of the parties here to have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

Said.....(For the Purchaser)

Name –

Address - IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

Designation -

In the presence of witness.....

Signature

Name

Address- IDPL Complex, Old-Delhi-Gurgaon Road, Dundehera, Gurgaon 122016 (Haryana)

Designation – Executive (Procurement)

Signed, Sealed and Delivered by the

Said.....(For the Supplier)

Name

Address

Designation

In the presence of witness

Signature

Name

Address Designation

ANNEXURE-XV

Ref. Clause No.14.1

SCHEDULE FOR PACKAGING OF DRUGS AND MEDICINES

GENERAL SPECIFICATIONS

1. Strips of Aluminum foils should be gauge 04.
2. Aluminum foils s back material for blisters should be gauge 025.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquerized Aluminum Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in this Schedule .
8. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminum strip / blisters with aluminum foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton should be of white board with a minimum of 300 GSM with **Gloss laminated/UV Varnished** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM.
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle.
15. All primary packaging should have BPPI toll free number 1800 180 8080

(Schedule)

1.	CORRUGATED BOXES(Liquid)
	1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box).
	2. All Corrugated boxes should be of `A` grade paper i.e. Virgin.
	3. All items should be packed only in first hand boxes only.

2.	FLUTE
	The corrugated boxes should be of narrow flute.
3.	JOINT
	Every box should be preferably single joint and not more than two joints.
4.	STITCHING
	Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	FLAP
	The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 - 60° should not crack.
6.	TAPE
	Every box should be sealed with gum tape running along the top and lower opening.
7.	CARRYSTRAP:
	Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	LABEL
	The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	OTHERS
	No box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION OF CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

- (1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.
- (2) The box should be of 5 ply with bursting strength of 9 Kg / Cm²

III. SPECIFICATIONS OF CORRUGATED BOXES FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

- (1) No corrugate box should weigh more than 7-8 Kgs.
- (2) Every Ointment tube should be individually packed in carton and then packed in 20's in a grey board box, which may be packed in a corrugated box.
- (3) Grammage: Outer box should be 150 gsm inside partition /
Lining should be 120gsm.

IV. SPECIFICATIONS OF CORRUGATED BOXES FOR INJECTABLE (IN VIALS AND AMPOULES)

- (1) Vials may be packed in corrugated boxes weighing upto 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.
- (2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while CB. For ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 5 ply.
- (3) Bursting strength for CB boxes for
 - i. Vials : Note less than 13 Kg/Cm²
 - ii. Amp : Note less than 9 Kg/Cm²
- (4) In the case of 10 ml Ampoules 100 or 50 ampoules may be packed in a grey board box. Multiples of grey board boxes packed in CB. In case of ampoules larger than 10 ml only 25 ampoules may be packed in a grey board box with partition.
- (5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.
- (6) In case of ampoules every grey board box should carry 5 amps. Cutters placed in a polythene bag.
- (7) Vials of eye, ear drops and nasal drops should be packed in an individual carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a grey board box.

ANNEXURE -XVI

Ref. clause 16.2

MANDATE FORM

Sl.No.	Details Required	
1.	Company Name	
2.	Postal Address of the Company	
	Telephone No.	
	Fax No.	
	E-mail ID	
	Alternate E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name: Designation:
	Mobile No.	
	E-mail ID	
5.	Bank Details	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **upload the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible.

I have read the conditions of the tender / agreement entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date:	Company Seal	Signature
Place:	(Name of the person signing & designation)	

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:
